Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific ABCA5 EST90625 ENSG00000154265 ATP-binding cassette, sub-family A (ABC1), member 5 17 69244311-69327244 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA022032 Approved Pancreatic cancer:9.97e-5 (favourable) Expressed in all Expressed in all skin: 28.0 ABCB9 EST122234 ENSG00000150967 ATP-binding cassette, sub-family B (MDR/TAP), member 9 12 122920951-122981649 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB033052, HPA035113, HPA035114 Approved Supported Vesicles Glioma:4.62e-4 (unfavourable) Mixed Tissue enhanced testis: 23.9 cerebral cortex: 12.1 ABCC9 CMD1O, SUR2 ENSG00000069431 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 12 21797401-21941402 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA007279 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:1.85e-5 (unfavourable) Mixed Mixed smooth muscle: 34.9 ABCD3 PMP70, PXMP1, ZWS2 ENSG00000117528 ATP-binding cassette, sub-family D (ALD), member 3 1 94418455-94518666 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA032026, HPA032027, CAB032516, CAB075749 Supported Validated Peroxisomes Colorectal cancer:1.16e-5 (favourable), Renal cancer:4.84e-5 (favourable) Expressed in all Expressed in all liver: 66.4 ABCD4 EST352188, P70R, PMP69, PXMP1L ENSG00000119688 ATP-binding cassette, sub-family D (ALD), member 4 14 74285423-74303056 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA003396 Approved Expressed in all Expressed in all fallopian tube: 13.6 ACKR1 CCBP1, CD234, DARC, Dfy, FY, GPD ENSG00000213088 Atypical chemokine receptor 1 (Duffy blood group) 1 159203307-159206500 Blood group antigen proteins, CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA016421, HPA017672 Supported Cervical cancer:2.52e-5 (favourable), Liver cancer:1.48e-4 (favourable), Thyroid cancer:9.76e-4 (unfavourable) Expressed in all Mixed adipose tissue: 111.8 ACKR2 CCBP2, CCR10, CCR9, CMKBR9, D6 ENSG00000144648 Atypical chemokine receptor 2 3 42804752-42887974 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013819, HPA073493 Supported Supported Nucleoplasm
Vesicles
Cytosol Mixed Tissue enhanced placenta: 22.8 adipose tissue: 5.2 ACSL3 ACS3, FACL3, PRO2194 ENSG00000123983 Acyl-CoA synthetase long-chain family member 3 2 222860934-222944639 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011315, HPA071021 Uncertain Approved Nucleoli
Lipid droplets Liver cancer:2.75e-4 (unfavourable), Lung cancer:8.78e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 670.1 ACSL4 ACS4, FACL4, LACS4, MRX63, MRX68 ENSG00000068366 Acyl-CoA synthetase long-chain family member 4 X 109624244-109733403 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000286, HPA005552 Supported Approved Golgi apparatus
Mitochondria Urothelial cancer:5.73e-4 (favourable) Expressed in all Expressed in all cervix, uterine: 70.3 ACSL5 ACS2, ACS5, FACL5 ENSG00000197142 Acyl-CoA synthetase long-chain family member 5 10 112374018-112428380 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA007162, CAB062546 Supported Supported Nucleus
Mitochondria Endometrial cancer:1.13e-4 (favourable) Expressed in all Expressed in all small intestine: 469.9 ACSL6 ACS2, FACL6, KIAA0837, LACS2, LACS5 ENSG00000164398 Acyl-CoA synthetase long-chain family member 6 5 131949973-132012243 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040470 Uncertain Group enriched Group enriched 6 bone marrow: 18.0;cerebral cortex: 62.1;parathyroid gland: 22.1;seminal vesicle: 28.7;testis: 51.2 adrenal gland: 6.5 ADCYAP1R1 PAC1, PAC1R, PACAPR ENSG00000078549 Adenylate cyclase activating polypeptide 1 (pituitary) receptor type I 7 31052461-31111479 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA049877 Approved Uncertain Vesicles Endometrial cancer:5.78e-4 (favourable) Tissue enriched Tissue enhanced cerebral cortex: 137.5;fallopian tube: 46.5 cervix, uterine: 20.6 ADGRB3 BAI3, KIAA0550 ENSG00000135298 Adhesion G protein-coupled receptor B3 6 68635367-69389511 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level Tissue enriched Tissue enriched 10 cerebral cortex: 53.2 adrenal gland: 5.2 ADGRD1 DKFZp434B1272, GPR133, PGR25 ENSG00000111452 Adhesion G protein-coupled receptor D1 12 130953907-131141469 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042395 Uncertain Approved Nucleus
Cytosol Liver cancer:9.27e-4 (unfavourable) Mixed Tissue enhanced placenta: 44.3 lung: 32.7 ADGRL4 ELTD1, ETL ENSG00000162618 Adhesion G protein-coupled receptor L4 1 78889764-79006718 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA025229 Supported Renal cancer:1.60e-4 (unfavourable) Expressed in all Mixed adipose tissue: 67.6 ADORA1 RDC7 ENSG00000163485 Adenosine A1 receptor 1 203090654-203167405 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA044383 Supported Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 46.5;testis: 23.4 parathyroid gland: 17.5 ADORA2A ADORA2, RDC8 ENSG00000128271 Adenosine A2a receptor 22 24417879-24442360 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Not detected Tissue enhanced bone marrow: 9.6 lymph node: 7.7 ADORA3 AD026 ENSG00000282608 Adenosine A3 receptor 1 111499429-111503760 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level Mixed adrenal gland: 18.5 AGPAT2 BSCL, LPAAT-beta ENSG00000169692 1-acylglycerol-3-phosphate O-acyltransferase 2 9 136673143-136687423 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA019544 Uncertain Approved Centrosome Expressed in all Expressed in all adipose tissue: 299.8 AGTRAP ATRAP ENSG00000177674 Angiotensin II receptor-associated protein 1 11736084-11754802 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA044120 Approved Supported Vesicles Liver cancer:6.57e-7 (unfavourable) Expressed in all Expressed in all prostate: 88.0 AIG1 AIG-1, dJ95L4.1, FLJ10485 ENSG00000146416 Androgen-induced 1 6 143060496-143340304 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA060766 Approved Approved Golgi apparatus Head and neck cancer:3.25e-7 (unfavourable), Cervical cancer:3.26e-6 (unfavourable), Endometrial cancer:3.06e-4 (unfavourable) Expressed in all Expressed in all liver: 153.9 ALDH3A2 ALDH10, ALDH3A2, FALDH , SLS ENSG00000072210 Aldehyde dehydrogenase 3 family, member A2 17 19648136-19677598 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014769, CAB020692 Approved Renal cancer:3.85e-8 (favourable) Expressed in all Expressed in all adrenal gland: 179.9 ALG12 ECM39 ENSG00000182858 ALG12, alpha-1,6-mannosyltransferase 22 49900229-49918458 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA003076, HPA051665 Approved Approved Endoplasmic reticulum Renal cancer:3.60e-5 (favourable), Endometrial cancer:6.09e-4 (favourable) Expressed in all Expressed in all thyroid gland: 17.1 ALG8 MGC2840 ENSG00000159063 ALG8, alpha-1,3-glucosyltransferase 11 78100936-78139660 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA051898 Approved Approved Nucleoplasm Expressed in all Expressed in all testis: 85.6 ALOX5AP FLAP ENSG00000132965 Arachidonate 5-lipoxygenase-activating protein 13 30713478-30764426 Disease related genes, Predicted membrane proteins Evidence at protein level HPA026592 Supported Renal cancer:5.68e-4 (unfavourable), Ovarian cancer:6.44e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 302.3 ANO10 FLJ10375, MGC47890, SCAR10, TMEM16K ENSG00000160746 Anoctamin 10 3 43354859-43691594 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051569 Approved Renal cancer:6.41e-6 (favourable), Endometrial cancer:1.11e-4 (favourable), Liver cancer:3.19e-4 (unfavourable), Colorectal cancer:6.70e-4 (favourable) Expressed in all Expressed in all duodenum: 64.3 ANO2 C12orf3, TMEM16B ENSG00000047617 Anoctamin 2, calcium activated chloride channel 12 5531869-5946232 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036276 Supported Nucleoplasm
Plasma membrane Tissue enhanced Tissue enhanced testis: 17.7 placenta: 5.9 ANO7 IPCA-5, NGEP, PCANAP5, PCANAP5L, TMEM16G ENSG00000146205 Anoctamin 7 2 241188509-241225377 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035730 Uncertain Tissue enriched Tissue enhanced prostate: 86.9;stomach: 26.2 small intestine: 15.7 APH1A APH-1A, CGI-78 ENSG00000117362 APH1A gamma secretase subunit 1 150265399-150269580 Predicted membrane proteins Evidence at protein level CAB037272 Approved Expressed in all Expressed in all thyroid gland: 160.6 APH1B APH-1B, DKFZp564D0372, PSFL ENSG00000138613 APH1B gamma secretase subunit 15 63276018-63309126 Predicted membrane proteins Evidence at protein level Pancreatic cancer:1.05e-4 (favourable), Renal cancer:2.25e-4 (favourable) Expressed in all Tissue enhanced testis: 153.1 thyroid gland: 32.0 APOLD1 DKFZP434F0318, FLJ25138 ENSG00000178878 Apolipoprotein L domain containing 1 12 12725917-12829975 Predicted membrane proteins Evidence at protein level HPA052462, HPA058882 Approved Validated Nucleoplasm
Cytosol Expressed in all Tissue enhanced adipose tissue: 142.0 placenta: 121.8 AQP1 CHIP28, CO ENSG00000240583 Aquaporin 1 (Colton blood group) 7 30911855-30925516 Blood group antigen proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB001707, HPA019206 Supported Supported Plasma membrane Renal cancer:1.32e-8 (favourable), Head and neck cancer:6.52e-4 (favourable) Expressed in all Expressed in all kidney: 801.2 AQP6 AQP2L ENSG00000086159 Aquaporin 6, kidney specific 12 49967194-49977139 Predicted membrane proteins, Transporters Evidence at protein level HPA015278 Supported Tissue enriched Tissue enriched 9 kidney: 20.8 cerebral cortex: 2.3 AQP7 AQP7L, AQP9, AQPap ENSG00000165269 Aquaporin 7 9 33383179-33402682 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:9.21e-8 (favourable) Mixed Tissue enhanced adipose tissue: 315.4 parathyroid gland: 65.5 ARL6IP5 DERP11, GTRAP3-18, HSPC127, JWA, PRAF3 ENSG00000144746 ADP-ribosylation factor-like 6 interacting protein 5 3 69084944-69106066 Predicted membrane proteins Evidence at protein level HPA015540, CAB019321 Supported Approved Endoplasmic reticulum Expressed in all Expressed in all prostate: 217.5 ARL6IP6 MGC33864 ENSG00000177917 ADP-ribosylation factor-like 6 interacting protein 6 2 152717893-152761253 Predicted membrane proteins Evidence at protein level HPA014743 Approved Approved Nuclear membrane
Cytosol Liver cancer:1.73e-4 (unfavourable), Renal cancer:2.14e-4 (unfavourable) Expressed in all Mixed placenta: 7.5 ARSE CDPX, CDPX1 ENSG00000157399 Arylsulfatase E (chondrodysplasia punctata 1) X 2934632-2968310 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA060518 Supported Golgi apparatus Colorectal cancer:8.95e-4 (favourable) Mixed Tissue enhanced kidney: 41.1;liver: 49.1 pancreas: 23.9 ATL2 ARL6IP2 ENSG00000119787 Atlastin GTPase 2 2 38294880-38377285 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029108 Approved Endometrial cancer:4.51e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 100.9 ATP10A ATP10C, ATPVA, ATPVC, KIAA0566 ENSG00000206190 ATPase, class V, type 10A 15 25677273-25865172 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA041496, HPA042509 Uncertain Renal cancer:6.60e-5 (unfavourable) Expressed in all Mixed lung: 10.5 ATP11C ATPIG, ATPIQ ENSG00000101974 ATPase, class VI, type 11C X 139726346-139945276 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA030830 Approved Expressed in all Mixed liver: 25.6 ATP13A2 CLN12, HSA9947, PARK9 ENSG00000159363 ATPase type 13A2 1 16985958-17011928 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB037038, CAB037111, HPA050910, HPA054717 Approved Liver cancer:3.33e-7 (unfavourable) Expressed in all Expressed in all cerebral cortex: 75.0 ATP13A3 AFURS1 ENSG00000133657 ATPase type 13A3 3 194402672-194498364 Predicted membrane proteins Evidence at protein level HPA029471 Approved Approved Nucleoli
Plasma membrane
Cytosol Pancreatic cancer:1.60e-4 (unfavourable), Renal cancer:1.63e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 146.4 ATP13A4 DKFZp761I1011, FLJ37958 ENSG00000127249 ATPase type 13A4 3 193402077-193593111 Disease related genes, Predicted membrane proteins Evidence at protein level HPA051932 Approved Nucleoplasm Head and neck cancer:3.91e-4 (favourable) Tissue enhanced Tissue enhanced epididymis: 89.1;parathyroid gland: 129.5;thyroid gland: 68.2 lung: 56.5 ATP1A1 ENSG00000163399 ATPase, Na+/K+ transporting, alpha 1 polypeptide 1 116372668-116410261 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB018702, CAB069993 Supported Renal cancer:8.98e-8 (favourable), Liver cancer:1.42e-4 (unfavourable), Urothelial cancer:4.01e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 2441.5 ATP1A4 ATP1AL2 ENSG00000132681 ATPase, Na+/K+ transporting, alpha 4 polypeptide 1 160151570-160186977 Enzymes, Predicted membrane proteins Evidence at protein level Urothelial cancer:2.20e-4 (favourable) Group enriched Tissue enhanced placenta: 10.1;testis: 18.1;urinary bladder: 8.9 lymph node: 4.1 ATP2C1 ATP2C1A, BCPM, KIAA1347, PMR1, SPCA1 ENSG00000017260 ATPase, Ca++ transporting, type 2C, member 1 3 130850595-131016712 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB010207, HPA035116, HPA069684 Supported Validated Golgi apparatus Liver cancer:5.06e-6 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Renal cancer:1.55e-4 (favourable) Expressed in all Expressed in all prostate: 136.8 ATP6V0A2 a2, ATP6a2, ATP6N1D, J6B7, Stv1, TJ6, TJ6M, TJ6s, Vph1 ENSG00000185344 ATPase, H+ transporting, lysosomal V0 subunit a2 12 123712318-123761755 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044279 Approved Approved Plasma membrane
Cytosol Expressed in all Expressed in all skin: 15.2 ATP6V0B ATP6F, HATPL, VMA16 ENSG00000117410 ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b 1 43974487-43978295 Predicted membrane proteins Evidence at transcript level HPA044281 Approved Cytosol Renal cancer:3.62e-6 (favourable), Pancreatic cancer:3.24e-4 (favourable), Liver cancer:4.79e-4 (unfavourable), Urothelial cancer:8.87e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 181.8 ATP6V0C ATP6C, ATP6L, ATPL, VATL, Vma3 ENSG00000185883 ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c 16 2513870-2520218 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA065100 Approved Cytosol Renal cancer:1.07e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 424.2 ATP9B ATPIIB ENSG00000166377 ATPase, class II, type 9B 18 79069285-79378283 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029364 Approved Expressed in all Expressed in all testis: 39.0 AVPR1A AVPR1 ENSG00000166148 Arginine vasopressin receptor 1A 12 63142759-63150942 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced adrenal gland: 78.3 adipose tissue: 19.9 BCAP29 BAP29, DKFZp686M2086 ENSG00000075790 B-cell receptor-associated protein 29 7 107579977-107629170 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA029215, HPA049694 Supported Approved Cytosol Liver cancer:3.62e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 185.4 BCAP31 6C6-Ag, BAP31, CDM, DXS1357E ENSG00000185825 B-cell receptor-associated protein 31 X 153700497-153724697 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA003906, CAB015350, CAB015424 Supported Approved Validated Endoplasmic reticulum Head and neck cancer:9.87e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 272.6 BEST1 BEST, BMD, RP50, VMD2 ENSG00000167995 Bestrophin 1 11 61949821-61965515 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA057464 Supported Group enriched Mixed cerebral cortex: 17.0 BFAR BAR, RNF47 ENSG00000103429 Bifunctional apoptosis regulator 16 14632815-14669236 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Pancreatic cancer:4.74e-5 (unfavourable) Expressed in all Expressed in all placenta: 23.3 BRI3BP BNAS1, HCCR-2, KG19 ENSG00000184992 BRI3 binding protein 12 124993700-125031231 Predicted membrane proteins, Transporters Evidence at protein level HPA014957 Approved Approved Nucleoplasm
Mitochondria Liver cancer:6.87e-4 (unfavourable) Expressed in all Mixed duodenum: 21.1 BSCL2 GNG3LG, SPG17 ENSG00000168000 Berardinelli-Seip congenital lipodystrophy 2 (seipin) 11 62690275-62709845 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042394 Approved Renal cancer:7.55e-5 (favourable) Expressed in all Expressed in all testis: 249.9 BVES HBVES, POP1, POPDC1 ENSG00000112276 Blood vessel epicardial substance 6 105096822-105137174 Predicted membrane proteins Evidence at protein level HPA014788, HPA018176 Supported Supported Cell Junctions Mixed Tissue enhanced smooth muscle: 24.7 testis: 20.7 C16orf52 ENSG00000185716 Chromosome 16 open reading frame 52 16 22007638-22087534 Predicted membrane proteins Evidence at transcript level Expressed in all Expressed in all parathyroid gland: 39.5 C16orf58 FLJ13868 ENSG00000140688 Chromosome 16 open reading frame 58 16 31489471-31509309 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024406 Uncertain Approved Nucleoplasm
Nucleoli
Golgi apparatus
Vesicles
Cytosol Expressed in all Expressed in all parathyroid gland: 81.3 C1orf101 MGC33370 ENSG00000179397 Chromosome 1 open reading frame 101 1 244454377-244641177 Predicted membrane proteins Evidence at protein level Not detected Tissue enriched 12 testis: 38.3 epididymis: 3.1 C20orf24 PNAS-11, RIP5 ENSG00000101084 Chromosome 20 open reading frame 24 20 36605734-36612557 Predicted membrane proteins Evidence at protein level HPA057387 Uncertain Approved Cytosol Liver cancer:4.56e-6 (unfavourable), Renal cancer:2.46e-4 (unfavourable) Expressed in all Expressed in all esophagus: 83.3 C3AR1 AZ3B, C3AR ENSG00000171860 Complement component 3a receptor 1 12 8058302-8066471 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB009405 Supported Expressed in all Tissue enhanced appendix: 88.4 placenta: 49.2 C5orf42 FLJ13231, JBTS17 ENSG00000197603 Chromosome 5 open reading frame 42 5 37106228-37249428 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036775, HPA036776 Approved Approved Cytosol Mixed Mixed thyroid gland: 13.7 C6orf47 D6S53E, G4 ENSG00000204439 Chromosome 6 open reading frame 47 6 31658298-31660772 Predicted membrane proteins Evidence at protein level HPA045281, HPA053373 Uncertain Approved Cytosol Expressed in all Mixed skin: 5.4 CACFD1 C9orf7, D9S2135, flower ENSG00000160325 Calcium channel flower domain containing 1 9 133459965-133470848 Predicted membrane proteins, Transporters Evidence at protein level HPA015280 Approved Nucleoplasm Renal cancer:2.83e-8 (favourable) Expressed in all Expressed in all thyroid gland: 16.6 CACNA1C CACH2, CACN2, CACNL1A1, Cav1.2, CCHL1A1, LQT8, TS ENSG00000151067 Calcium channel, voltage-dependent, L type, alpha 1C subunit 12 1970786-2697950 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA039796 Supported Mixed Tissue enhanced smooth muscle: 30.9 endometrium: 26.2 CACNA1D CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2 ENSG00000157388 Calcium channel, voltage-dependent, L type, alpha 1D subunit 3 53494656-53813733 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA020215 Uncertain Approved Nuclear membrane Renal cancer:8.34e-8 (favourable) Mixed Mixed fallopian tube: 13.7 CACNG1 CACNLG ENSG00000108878 Calcium channel, voltage-dependent, gamma subunit 1 17 67044590-67056797 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Tissue enhanced Tissue enriched 25 skeletal muscle: 113.5 esophagus: 4.4 CACNG5 ENSG00000075429 Calcium channel, voltage-dependent, gamma subunit 5 17 66835117-66885486 Predicted membrane proteins Evidence at protein level HPA050115 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 1.2 lymph node: 0.6 CACNG7 ENSG00000105605 Calcium channel, voltage-dependent, gamma subunit 7 19 53909335-53943941 Predicted membrane proteins, Transporters Evidence at protein level Tissue enriched Tissue enriched 101 cerebral cortex: 63.9 adrenal gland: 0.6 CATSPERB C14orf161, FLJ14298 ENSG00000133962 Catsper channel auxiliary subunit beta 14 91580696-91780707 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA035134 Uncertain Uncertain Vesicles Mixed Mixed skin: 2.7 CCKBR ENSG00000110148 Cholecystokinin B receptor 11 6259736-6272127 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Tissue enriched Group enriched 14 cerebral cortex: 13.7;pancreas: 5.4;stomach: 16.1 prostate: 0.8 CD151 PETA-3, RAPH, SFA-1, TSPAN24 ENSG00000177697 CD151 molecule (Raph blood group) 11 832843-839831 Blood group antigen proteins, CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002428, HPA011906 Supported Liver cancer:5.58e-4 (unfavourable), Thyroid cancer:6.92e-4 (favourable), Lung cancer:9.46e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 356.5 CD37 TSPAN26 ENSG00000104894 CD37 molecule 19 49335171-49343335 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002492, HPA032120, HPA032121 Supported Endometrial cancer:4.51e-4 (favourable) Expressed in all Tissue enhanced lymph node: 244.2;spleen: 212.9 appendix: 133.5 CD63 ME491, MLA1, TSPAN30 ENSG00000135404 CD63 molecule 12 55725323-55729707 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA010088, CAB026356 Supported Supported Vesicles Liver cancer:1.37e-4 (unfavourable) Expressed in all Expressed in all epididymis: 1712.6 CD81 TAPA-1, TAPA1, TSPAN28 ENSG00000110651 CD81 molecule 11 2376177-2397419 CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002507, HPA007234 Supported Supported Plasma membrane Glioma:5.12e-5 (unfavourable), Pancreatic cancer:3.86e-4 (favourable), Colorectal cancer:7.56e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 2246.2 CD82 IA4, KAI1, R2, ST6, TSPAN27 ENSG00000085117 CD82 molecule 11 44564427-44620363 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002508, HPA028900, HPA061418 Supported Approved Vesicles Expressed in all Expressed in all esophagus: 132.1 CD9 BA2, MIC3, MRP-1, P24, TSPAN29 ENSG00000010278 CD9 molecule 12 6199715-6238271 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB002490 Supported Supported Plasma membrane Renal cancer:6.49e-5 (favourable), Thyroid cancer:8.93e-5 (favourable), Pancreatic cancer:1.59e-4 (unfavourable) Expressed in all Expressed in all esophagus: 1009.8 CDH11 CAD11, OB ENSG00000140937 Cadherin 11, type 2, OB-cadherin (osteoblast) 16 64943753-65126112 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB013072 Approved Renal cancer:2.48e-9 (unfavourable) Expressed in all Tissue enhanced ovary: 223.0 placenta: 172.7 CDIPT PIS, PIS1 ENSG00000103502 CDP-diacylglycerol--inositol 3-phosphatidyltransferase 16 29858357-29863736 Enzymes, Predicted membrane proteins Evidence at protein level HPA056597 Approved Approved Nucleoplasm
Nuclear membrane
Plasma membrane Cervical cancer:9.40e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 110.5 CERS2 FLJ10243, LASS2, SP260 ENSG00000143418 Ceramide synthase 2 1 150960583-150975004 Predicted membrane proteins Evidence at protein level HPA027262 Approved Supported Nuclear membrane
Endoplasmic reticulum Expressed in all Expressed in all liver: 408.6 CHRM1 ENSG00000168539 Cholinergic receptor, muscarinic 1 11 62908679-62921807 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014101, CAB022366 Supported Approved Nucleus
Cytosol Tissue enriched Group enriched 6 cerebral cortex: 40.0;prostate: 40.1;salivary gland: 11.1 breast: 4.7 CHRNA3 ENSG00000080644 Cholinergic receptor, nicotinic, alpha 3 (neuronal) 15 78593052-78621295 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029430 Approved Mixed Tissue enriched 7 adrenal gland: 48.2 appendix: 6.5 CKLF C32, CKLF1, CKLF3, CKLF4, HSPC224, UCK-1 ENSG00000217555 Chemokine-like factor 16 66552563-66566251 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA062779 Approved Vesicles Renal cancer:1.06e-9 (unfavourable), Liver cancer:5.67e-5 (unfavourable), Thyroid cancer:2.22e-4 (favourable) Expressed in all Expressed in all testis: 91.2 CLCC1 MCLC ENSG00000121940 Chloride channel CLIC-like 1 1 108929508-108963457 Predicted membrane proteins, Transporters Evidence at protein level HPA009087, HPA013210 Supported Validated Endoplasmic reticulum Colorectal cancer:1.33e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 38.0 CLCN7 CLC-7, CLC7, OPTA2, PPP1R63 ENSG00000103249 Chloride channel, voltage-sensitive 7 16 1444934-1475580 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA043019, HPA043586 Supported Supported Nucleoplasm Testis cancer:3.21e-4 (unfavourable), Head and neck cancer:5.23e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 40.4 CLDN1 ILVASC, SEMP1 ENSG00000163347 Claudin 1 3 190305701-190322475 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002602, HPA048319 Supported Endometrial cancer:2.00e-4 (unfavourable), Pancreatic cancer:5.23e-4 (unfavourable) Expressed in all Tissue enhanced skin: 306.9;smooth muscle: 183.5 liver: 158.3 CLDN10 CPETRL3, OSP-L ENSG00000134873 Claudin 10 13 95433604-95579759 Predicted membrane proteins Evidence at protein level CAB012969, HPA042348 Supported Renal cancer:7.46e-5 (favourable), Thyroid cancer:2.13e-4 (favourable) Mixed Tissue enhanced kidney: 161.8 gallbladder: 111.0 CLDN11 OSP, OTM ENSG00000013297 Claudin 11 3 170418865-170860380 Predicted membrane proteins Evidence at protein level CAB009789, HPA013166 Supported Breast cancer:6.31e-4 (favourable) Tissue enhanced Tissue enhanced cerebral cortex: 89.2;testis: 184.3 ovary: 61.8 CLDN12 ENSG00000157224 Claudin 12 7 90383721-90513402 Predicted membrane proteins Evidence at protein level HPA026945 Approved Cervical cancer:6.36e-4 (unfavourable) Expressed in all Expressed in all prostate: 40.8 CLDN14 DFNB29 ENSG00000159261 Claudin 14 21 36460621-36576569 Disease related genes, Predicted membrane proteins Evidence at protein level Liver cancer:1.53e-4 (favourable) Tissue enriched Group enriched 11 kidney: 3.6;liver: 9.6 gallbladder: 0.6 CLDN15 ENSG00000106404 Claudin 15 7 101232092-101238820 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level Renal cancer:5.31e-5 (unfavourable), Pancreatic cancer:2.56e-4 (favourable), Urothelial cancer:3.30e-4 (favourable) Expressed in all Group enriched 16 duodenum: 248.2;small intestine: 187.4 spleen: 13.5 CLDN17 MGC126552, MGC126554 ENSG00000156282 Claudin 17 21 30165564-30166756 Predicted membrane proteins, Transporters Evidence at protein level HPA045903 Supported Tissue enhanced Tissue enriched 5 esophagus: 6.6 tonsil: 1.3 CLDN18 SFTPJ ENSG00000066405 Claudin 18 3 137998735-138033655 Predicted membrane proteins Evidence at protein level CAB013010, CAB013243, HPA018446 Supported Group enriched Group enriched 99 lung: 362.1;stomach: 695.3 gallbladder: 5.3 CLDN19 ENSG00000164007 Claudin 19 1 42733093-42740254 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level Tissue enhanced Group enriched 12 kidney: 19.6;placenta: 14.4 breast: 1.4 CLDN20 ENSG00000171217 Claudin 20 6 155264013-155276548 Predicted membrane proteins Evidence at transcript level Mixed Mixed skin: 1.0 CLDN22 CLDN21 ENSG00000177300 Claudin 22 4 183318194-183320774 Predicted membrane proteins, Transporters Evidence at transcript level Not detected Not detected epididymis,esophagus: 0.1 CLDN23 CLDNL ENSG00000253958 Claudin 23 8 8701938-8704106 Predicted membrane proteins, Transporters Evidence at protein level HPA070578 Uncertain Nucleus
Plasma membrane Renal cancer:9.65e-8 (favourable), Colorectal cancer:3.46e-4 (favourable) Expressed in all Tissue enhanced colon: 24.1;stomach: 24.9 small intestine: 16.9 CLDN24 CLDN21 ENSG00000185758 Claudin 24 4 183321764-183322426 Predicted membrane proteins Evidence at transcript level Not detected Tissue enhanced kidney: 1.0 esophagus,smooth muscle: 0.2 CLDN25 ENSG00000228607 Claudin 25 11 113779747-113780500 Predicted membrane proteins No evidence HPA053555 Uncertain Not detected Not detected epididymis: 0.1 CLDN4 CPE-R, CPETR, CPETR1, hCPE-R, WBSCR8 ENSG00000189143 Claudin 4 7 73799542-73832693 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002610 Supported Supported Plasma membrane Renal cancer:3.46e-10 (favourable), Ovarian cancer:3.28e-4 (unfavourable) Mixed Mixed colon: 212.3 CLDN5 AWAL, BEC1, CPETRL1, TMVCF ENSG00000184113 Claudin 5 22 19523024-19527545 Predicted membrane proteins, Transporters Evidence at protein level CAB002607 Approved Expressed in all Tissue enhanced adipose tissue: 128.2 lung: 53.8 CLDN6 ENSG00000184697 Claudin 6 16 3014712-3020071 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Endometrial cancer:2.42e-6 (unfavourable), Urothelial cancer:1.78e-4 (unfavourable) Group enriched Tissue enhanced placenta: 1.0;testis: 1.8 cerebral cortex,lung,parathyroid gland: 0.3 CLDN7 CEPTRL2, CPETRL2, Hs.84359 ENSG00000181885 Claudin 7 17 7259903-7263983 Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB013063, HPA014703, HPA073662 Supported Approved Vesicles
Cell Junctions Renal cancer:8.96e-11 (favourable), Thyroid cancer:1.85e-4 (favourable), Stomach cancer:4.09e-4 (favourable) Expressed in all Mixed small intestine: 357.1 CLDN9 ENSG00000213937 Claudin 9 16 3012456-3014505 Predicted membrane proteins Evidence at protein level HPA076613 Supported Vesicles
Cell Junctions Endometrial cancer:2.24e-6 (unfavourable), Stomach cancer:4.67e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 3.1 bone marrow: 1.7 CLDND1 C3orf4 ENSG00000080822 Claudin domain containing 1 3 98497912-98523066 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA029841 Approved Approved Nucleus
Nucleoli
Cytosol Renal cancer:5.84e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 400.9 CLDND2 MGC33839 ENSG00000160318 Claudin domain containing 2 19 51367098-51369003 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA056971 Uncertain Approved Nucleoplasm Mixed Tissue enhanced testis: 22.3 spleen: 6.4 CLN3 BTS, JNCL ENSG00000188603 Ceroid-lipofuscinosis, neuronal 3 16 28477279-28495575 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA063280 Uncertain Expressed in all Expressed in all placenta: 54.9 CLN6 FLJ20561, HsT18960, nclf ENSG00000128973 Ceroid-lipofuscinosis, neuronal 6, late infantile, variant 15 68206992-68257211 Disease related genes, Predicted membrane proteins Evidence at protein level HPA066046, HPA074162 Approved Approved Vesicles Renal cancer:4.87e-4 (favourable) Expressed in all Expressed in all appendix: 23.0 CLPTM1L CRR9, FLJ14400 ENSG00000049656 CLPTM1-like 5 1317744-1345099 Predicted membrane proteins Evidence at protein level HPA014791 Approved Approved Endoplasmic reticulum Liver cancer:3.75e-4 (unfavourable) Expressed in all Expressed in all testis: 54.1 CLRN1 RP61, USH3, USH3A ENSG00000163646 Clarin 1 3 150926163-150972999 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA054636 Uncertain Not detected Tissue enhanced adrenal gland: 6.8;duodenum: 1.6 testis: 0.8 CLRN2 ENSG00000249581 Clarin 2 4 17515165-17527104 Predicted membrane proteins, Transporters Evidence at transcript level HPA042407 Uncertain Not detected Not detected testis: 0.3 CLRN3 MGC32871, TMEM12, USH3AL1 ENSG00000180745 Clarin 3 10 127877841-127892947 Predicted membrane proteins, Transporters Evidence at protein level HPA014482 Approved Stomach cancer:8.98e-4 (favourable) Group enriched Group enriched 8 colon: 71.2;duodenum: 75.4;gallbladder: 23.7;kidney: 43.9;liver: 40.2;rectum: 77.5;small intestine: 99.5 appendix: 7.5 CMKLR1 RVER1 ENSG00000174600 Chemerin chemokine-like receptor 1 12 108288044-108339341 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA047865 Uncertain Expressed in all Tissue enhanced spleen: 49.3 placenta: 40.0 CMTM1 CKLFH, CKLFH1a, CKLFSF1 ENSG00000089505 CKLF-like MARVEL transmembrane domain containing 1 16 66566393-66579137 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA013801, HPA017136 Uncertain Approved Nucleoplasm Pancreatic cancer:5.68e-5 (unfavourable) Mixed Tissue enriched 6 testis: 28.8 spleen: 4.5 CMTM3 BNAS2, CKLFSF3, FLJ31762 ENSG00000140931 CKLF-like MARVEL transmembrane domain containing 3 16 66603874-66613892 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013870 Approved Nucleoplasm Renal cancer:4.42e-6 (unfavourable), Stomach cancer:1.85e-4 (unfavourable) Expressed in all Expressed in all testis: 69.3 CMTM4 CKLFSF4 ENSG00000183723 CKLF-like MARVEL transmembrane domain containing 4 16 66614750-66696707 Predicted membrane proteins Evidence at protein level HPA014704, HPA023890 Supported Approved Golgi apparatus
Vesicles
Plasma membrane Renal cancer:4.72e-9 (favourable) Expressed in all Tissue enhanced thyroid gland: 63.9 parathyroid gland: 47.2 CMTM5 CKLFSF5, FLJ37521 ENSG00000166091 CKLF-like MARVEL transmembrane domain containing 5 14 23376808-23379772 Predicted membrane proteins Evidence at protein level HPA052338 Supported Group enriched Tissue enriched 20 cerebral cortex: 81.5 bone marrow,seminal vesicle: 4.0 CMTM6 CKLFSF6, FLJ20396 ENSG00000091317 CKLF-like MARVEL transmembrane domain containing 6 3 32481312-32503408 Predicted membrane proteins Evidence at protein level HPA026980 Approved Approved Intermediate filaments
Cytosol Expressed in all Expressed in all fallopian tube: 236.7 CMTM7 CKLFSF7, FLJ30992 ENSG00000153551 CKLF-like MARVEL transmembrane domain containing 7 3 32391671-32483067 Predicted membrane proteins, Transporters Evidence at protein level HPA077409 Approved Plasma membrane Renal cancer:1.00e-6 (unfavourable), Liver cancer:3.21e-4 (unfavourable) Expressed in all Mixed fallopian tube: 60.9 CNIH1 CNIH, CNIL, TGAM77 ENSG00000100528 Cornichon family AMPA receptor auxiliary protein 1 14 54423560-54441431 Predicted membrane proteins, Transporters Evidence at protein level HPA002544 Approved Approved Vesicles Urothelial cancer:8.95e-4 (unfavourable) Expressed in all Expressed in all liver: 118.5 CNIH2 CNIH-2, Cnil, MGC50896 ENSG00000174871 Cornichon family AMPA receptor auxiliary protein 2 11 66278190-66285301 Predicted membrane proteins Evidence at protein level Tissue enhanced Tissue enriched 11 cerebral cortex: 53.0 adrenal gland: 4.6 CNIH3 CNIH-3, FLJ38993 ENSG00000143786 Cornichon family AMPA receptor auxiliary protein 3 1 224434660-224740549 Predicted membrane proteins Evidence at transcript level Mixed Tissue enhanced cerebral cortex: 14.8 testis: 4.2 CNIH4 HSPC163 ENSG00000143771 Cornichon family AMPA receptor auxiliary protein 4 1 224356850-224379459 Predicted membrane proteins Evidence at protein level HPA044268 Approved Renal cancer:4.27e-6 (unfavourable), Head and neck cancer:1.72e-4 (unfavourable), Pancreatic cancer:4.61e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 27.1 CNOT1 AD-005, CDC39, KIAA1007, NOT1, NOT1H ENSG00000125107 CCR4-NOT transcription complex, subunit 1 16 58519951-58629886 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046577, HPA049664 Approved Supported Cytosol Expressed in all Expressed in all testis: 206.0 CRLS1 C20orf155, CLS1, dJ967N21.6, GCD10 ENSG00000088766 Cardiolipin synthase 1 20 6006090-6040053 Enzymes, Predicted membrane proteins Evidence at protein level Urothelial cancer:8.02e-4 (favourable) Expressed in all Expressed in all liver: 86.7 CXCR2 CD182, CMKAR2, IL8RB ENSG00000180871 Chemokine (C-X-C motif) receptor 2 2 218125289-218137253 Cancer-related genes, CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB016268, HPA031999, HPA032017 Supported Mixed Tissue enhanced appendix: 56.9;spleen: 37.2 esophagus: 30.0 CYB561 CYB561A1, FRRS2 ENSG00000008283 Cytochrome b561 17 63432304-63446378 Predicted membrane proteins, Transporters Evidence at protein level HPA014753 Approved Endometrial cancer:2.95e-5 (favourable), Breast cancer:8.89e-5 (unfavourable) Expressed in all Expressed in all adrenal gland: 164.3 CYB561A3 CYBASC3 ENSG00000162144 Cytochrome b561 family, member A3 11 61348745-61362299 Predicted membrane proteins Evidence at protein level HPA052548 Uncertain Expressed in all Expressed in all adrenal gland: 188.0 CYBA p22-PHOX ENSG00000051523 Cytochrome b-245, alpha polypeptide 16 88643283-88651152 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB009492 Supported Endometrial cancer:4.75e-5 (favourable), Renal cancer:1.83e-4 (unfavourable), Breast cancer:8.19e-4 (favourable) Expressed in all Expressed in all spleen: 476.3 CYHR1 CHRP, KIAA0496, MGC13010 ENSG00000187954 Cysteine/histidine-rich 1 8 144449582-144465677 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA053653, HPA059543 Approved Validated Nucleoplasm Colorectal cancer:1.05e-4 (unfavourable), Liver cancer:3.90e-4 (unfavourable) Expressed in all Expressed in all testis: 51.5 CYP3A4 CYP3A3 ENSG00000160868 Cytochrome P450, family 3, subfamily A, polypeptide 4 7 99756960-99784265 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB033671, HPA072245 Supported Uncertain Cytosol Tissue enriched Group enriched 200 duodenum: 849.6;liver: 2446.6;small intestine: 990.4 adrenal gland: 7.1 DAD1 OST2 ENSG00000129562 Defender against cell death 1 14 22564905-22589269 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level HPA028882 Uncertain Approved Cytosol Liver cancer:7.73e-4 (unfavourable) Expressed in all Expressed in all epididymis: 507.2 DAGLB DAGLBETA, KCCR13L ENSG00000164535 Diacylglycerol lipase, beta 7 6409126-6484190 Predicted membrane proteins Evidence at protein level HPA069377 Supported Plasma membrane Ovarian cancer:7.18e-5 (unfavourable), Renal cancer:1.54e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 20.6 DAPL1 ENSG00000163331 Death associated protein-like 1 2 158795317-158862958 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046937 Approved Nucleoplasm
Mitochondria Cervical cancer:8.43e-4 (favourable) Group enriched Tissue enhanced epididymis: 236.1;esophagus: 245.6;skin: 219.1 fallopian tube: 128.2 DCSTAMP DC-STAMP, FIND, TM7SF4 ENSG00000164935 Dendrocyte expressed seven transmembrane protein 8 104339087-104356689 Predicted membrane proteins Evidence at protein level Tissue enriched Group enriched 10 epididymis: 2.3;lung: 5.6 cervix, uterine: 0.4 DERL2 CGI-101, derlin-2, F-LAN-1, F-LANa, FLANa ENSG00000072849 Derlin 2 17 5471251-5486811 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037287, HPA048957, HPA056551 Supported Supported Endoplasmic reticulum Renal cancer:6.49e-4 (unfavourable), Endometrial cancer:7.26e-4 (favourable) Expressed in all Expressed in all thyroid gland: 41.3 DHCR7 SLOS ENSG00000172893 7-dehydrocholesterol reductase 11 71428193-71452868 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA044280 Approved Supported Endoplasmic reticulum
Cytosol Renal cancer:6.93e-7 (favourable), Urothelial cancer:5.67e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 116.0 DOLPP1 LSFR2 ENSG00000167130 Dolichyldiphosphatase 1 9 129081100-129090438 Enzymes, Predicted membrane proteins Evidence at protein level HPA019179 Approved Approved Vesicles
Intermediate filaments Expressed in all Expressed in all duodenum: 26.5 DRAM1 DRAM, FLJ11259 ENSG00000136048 DNA-damage regulated autophagy modulator 1 12 101877351-102012130 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Endometrial cancer:6.52e-8 (favourable), Renal cancer:3.91e-4 (unfavourable) Expressed in all Expressed in all lung: 133.6 EBP CDPX2, CHO2, CPX, CPXD ENSG00000147155 Emopamil binding protein (sterol isomerase) X 48521158-48528716 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA003130 Approved Supported Endoplasmic reticulum Expressed in all Expressed in all liver: 91.1 EDNRA ENSG00000151617 Endothelin receptor type A 4 147480917-147544954 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013774, CAB018957 Uncertain Renal cancer:1.50e-7 (unfavourable), Stomach cancer:3.93e-4 (unfavourable) Expressed in all Tissue enhanced seminal vesicle: 145.4 cervix, uterine: 82.6 EI24 EPG4, PIG8, TP53I8 ENSG00000149547 Etoposide induced 2.4 11 125569216-125584687 Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA047165, HPA051029 Uncertain Supported Endoplasmic reticulum
Golgi apparatus
Cytosol Pancreatic cancer:9.28e-4 (unfavourable) Expressed in all Tissue enriched 9 parathyroid gland: 1098.6 liver: 124.7 ELOVL6 FLJ23378, LCE, MGC5487 ENSG00000170522 ELOVL fatty acid elongase 6 4 110045846-110199199 Enzymes, Predicted membrane proteins Evidence at protein level HPA042355 Uncertain Colorectal cancer:6.74e-4 (favourable) Expressed in all Mixed liver: 27.9 EMC3 TMEM111 ENSG00000125037 ER membrane protein complex subunit 3 3 9962537-10011116 Predicted membrane proteins Evidence at protein level HPA042372 Approved Approved Microtubules
Cytosol Renal cancer:2.81e-6 (favourable) Expressed in all Expressed in all testis: 90.7 EMP1 CL-20, TMP ENSG00000134531 Epithelial membrane protein 1 12 13196716-13219939 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051931, HPA056250 Approved Nucleoplasm Ovarian cancer:2.26e-8 (unfavourable), Urothelial cancer:9.69e-8 (unfavourable), Pancreatic cancer:7.46e-4 (unfavourable) Expressed in all Expressed in all esophagus: 2208.3 EMP2 XMP ENSG00000213853 Epithelial membrane protein 2 16 10528422-10580698 Disease related genes, Predicted membrane proteins Evidence at protein level HPA014711 Approved Approved Nucleoplasm
Cytosol Renal cancer:2.85e-8 (unfavourable), Glioma:1.93e-4 (unfavourable) Expressed in all Tissue enhanced lung: 344.5 skin: 166.7 EMP3 YMP ENSG00000142227 Epithelial membrane protein 3 19 48321509-48330553 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051163 Approved Nuclear bodies Renal cancer:2.31e-7 (unfavourable), Stomach cancer:3.13e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 199.1 ENDOD1 KIAA0830 ENSG00000149218 Endonuclease domain containing 1 11 95089810-95132645 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA008932, HPA010517 Supported Approved Nuclear membrane Renal cancer:6.64e-7 (favourable), Urothelial cancer:3.27e-4 (unfavourable), Pancreatic cancer:8.86e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 97.8 EPT1 KIAA1724, SELI, SEPI ENSG00000138018 Ethanolaminephosphotransferase 1 2 26308547-26395891 Enzymes, Predicted membrane proteins Evidence at protein level Expressed in all Expressed in all parathyroid gland: 33.1 F2RL1 GPR11, PAR2 ENSG00000164251 Coagulation factor II (thrombin) receptor-like 1 5 76818933-76835315 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level CAB012989, HPA014091 Approved Approved Plasma membrane Renal cancer:5.86e-7 (favourable), Colorectal cancer:3.88e-4 (favourable), Head and neck cancer:5.88e-4 (unfavourable), Lung cancer:8.92e-4 (unfavourable) Expressed in all Mixed colon: 59.9 FADS1 D5D, FADS6, FADSD5, LLCDL1, TU12 ENSG00000149485 Fatty acid desaturase 1 11 61799625-61829318 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042705 Approved Renal cancer:1.95e-9 (unfavourable), Urothelial cancer:1.33e-4 (unfavourable), Thyroid cancer:2.79e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 89.6 FADS3 CYB5RP, LLCDL3 ENSG00000221968 Fatty acid desaturase 3 11 61873519-61892051 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045224 Approved Renal cancer:1.50e-9 (unfavourable), Head and neck cancer:9.54e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 98.7 FAM122C RP3-473B4.1 ENSG00000156500 Family with sequence similarity 122C X 134796789-134854610 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA059961 Approved Uncertain Nucleoplasm Mixed Mixed testis: 7.8 FAM134C DKFZp686B1036, FLJ33806 ENSG00000141699 Family with sequence similarity 134, member C 17 42579513-42610623 Predicted membrane proteins Evidence at protein level HPA016492 Uncertain Approved Nucleoplasm
Nuclear membrane
Cytosol Endometrial cancer:1.61e-4 (favourable), Renal cancer:6.82e-4 (unfavourable) Expressed in all Expressed in all testis: 48.6 FAM160A2 C11orf56, DKFZP566M1046, FLJ22665, KIAA1759 ENSG00000051009 Family with sequence similarity 160, member A2 11 6211335-6234711 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055994, HPA063987 Approved Approved Mitochondria Expressed in all Expressed in all testis: 42.2 FAM189B C1orf2, cote1 ENSG00000160767 Family with sequence similarity 189, member B 1 155247205-155255483 Predicted membrane proteins Evidence at protein level HPA006659, HPA050674 Uncertain Supported Nucleoplasm Renal cancer:3.43e-7 (unfavourable), Endometrial cancer:9.59e-5 (unfavourable), Liver cancer:3.43e-4 (unfavourable), Cervical cancer:4.98e-4 (unfavourable) Expressed in all Mixed seminal vesicle: 6.7 FAM57B DKFZP434I2117 ENSG00000149926 Family with sequence similarity 57, member B 16 30024427-30052978 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030837 Uncertain Tissue enriched Group enriched 12 cerebral cortex: 18.7;testis: 77.3 skeletal muscle: 3.9 FAM8A1 AHCP ENSG00000137414 Family with sequence similarity 8, member A1 6 17600355-17611719 Predicted membrane proteins, Transporters Evidence at protein level HPA044698 Supported Golgi apparatus Expressed in all Expressed in all endometrium: 45.3 FAR2 FLJ10462, MLSTD1, SDR10E2 ENSG00000064763 Fatty acyl CoA reductase 2 12 29149103-29340980 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015884 Approved Approved Nucleoli
Golgi apparatus Renal cancer:4.93e-4 (unfavourable) Expressed in all Mixed epididymis: 52.9 FP325317.1 ENSG00000277737 9 43109628-43127172 Predicted membrane proteins Evidence at transcript level Not detected Tissue enriched 8 adipose tissue: 38.3 heart muscle: 4.7 FPR2 ALXR, FMLP-R-II, FMLPX, FPR2A, FPRH2, FPRL1, HM63, LXA4R ENSG00000171049 Formyl peptide receptor 2 19 51752026-51770526 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA029154 Approved Mixed Tissue enhanced appendix: 71.3 spleen: 20.0 FXYD7 ENSG00000221946 FXYD domain containing ion transport regulator 7 19 35143250-35154301 Predicted membrane proteins Evidence at protein level HPA026916 Approved Tissue enhanced Tissue enriched 34 cerebral cortex: 106.1 lymph node: 3.1 G6PC G6PT, GSD1a ENSG00000131482 Glucose-6-phosphatase, catalytic subunit 17 42900797-42913369 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA052324 Approved Renal cancer:3.79e-5 (favourable), Liver cancer:5.42e-5 (favourable) Tissue enriched Tissue enhanced kidney: 88.4;liver: 146.8 small intestine: 33.8 GABRA2 ENSG00000151834 Gamma-aminobutyric acid (GABA) A receptor, alpha 2 4 46248427-46475230 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level Tissue enhanced Tissue enriched 6 cerebral cortex: 74.5 epididymis: 13.3 GABRB2 ENSG00000145864 Gamma-aminobutyric acid (GABA) A receptor, beta 2 5 161288429-161549044 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB001964, HPA067632 Supported Tissue enriched Tissue enriched 11 cerebral cortex: 63.0 epididymis: 5.5 GABRG3 ENSG00000182256 Gamma-aminobutyric acid (GABA) A receptor, gamma 3 15 26971282-27541991 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054010 Supported Tissue enhanced Tissue enhanced prostate: 10.6;testis: 16.4 cerebral cortex: 4.2 GABRP ENSG00000094755 Gamma-aminobutyric acid (GABA) A receptor, pi 5 170763350-170814047 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB014883 Uncertain Cervical cancer:3.37e-4 (favourable) Mixed Expressed in all breast: 186.6 GDPD5 GDE2, PP1665 ENSG00000158555 Glycerophosphodiester phosphodiesterase domain containing 5 11 75434640-75525903 Predicted membrane proteins Evidence at protein level HPA065257, HPA066762, HPA069281 Uncertain Approved Golgi apparatus Renal cancer:6.59e-9 (unfavourable), Endometrial cancer:1.29e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 68.0 testis: 31.2 GJA3 CX46, CZP3 ENSG00000121743 Gap junction protein, alpha 3, 46kDa 13 20138255-20161049 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA014821 Supported Tissue enhanced Tissue enhanced heart muscle: 4.7;parathyroid gland: 5.8;placenta: 3.5 testis: 2.5 GJA9 CX58, CX59, GJA10 ENSG00000131233 Gap junction protein, alpha 9, 59kDa 1 38874451-38881587 Predicted membrane proteins Evidence at transcript level HPA067850 Uncertain Not detected Tissue enhanced testis: 2.2 skin: 0.5 GJB7 bA136M9.1, CX25 ENSG00000164411 Gap junction protein, beta 7, 25kDa 6 87282978-87329278 Predicted membrane proteins Evidence at transcript level Mixed Tissue enhanced fallopian tube: 11.1;placenta: 3.8 testis: 1.5 GJC3 CX30.2, GJE1 ENSG00000176402 Gap junction protein, gamma 3, 30.2kDa 7 99923269-99929620 Predicted membrane proteins, Transporters Evidence at protein level HPA015024 Uncertain Group enriched Tissue enhanced breast: 8.9;prostate: 5.6 testis: 3.2 GLP2R ENSG00000065325 Glucagon-like peptide 2 receptor 17 9822206-9892102 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022690, HPA049244 Supported Supported Plasma membrane Tissue enhanced Tissue enhanced gallbladder: 19.4 duodenum: 10.4 GLRA4 ENSG00000188828 Glycine receptor, alpha 4 X 103707224-103728655 Predicted membrane proteins Evidence at transcript level HPA044759 Uncertain Not detected Tissue enhanced smooth muscle: 2.7 parathyroid gland: 1.0 GOLT1B CGI-141, GOT1, YMR292W ENSG00000111711 Golgi transport 1B 12 21501781-21518408 Predicted membrane proteins Evidence at protein level HPA055909, HPA066383 Approved Approved Vesicles Renal cancer:4.83e-10 (unfavourable), Liver cancer:1.99e-8 (unfavourable), Pancreatic cancer:2.32e-4 (unfavourable) Expressed in all Expressed in all placenta: 42.1 GPAT2 CT123 ENSG00000186281 Glycerol-3-phosphate acyltransferase 2, mitochondrial 2 96021946-96039451 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036841 Uncertain Approved Mitochondria Mixed Mixed testis: 7.3 GPM6B M6B, MGC17150, MGC54284 ENSG00000046653 Glycoprotein M6B X 13771031-13938638 Predicted membrane proteins Evidence at protein level HPA002913 Approved Ovarian cancer:2.67e-4 (favourable) Group enriched Tissue enriched 17 cerebral cortex: 838.3 seminal vesicle: 48.9 GPR1 ENSG00000183671 G protein-coupled receptor 1 2 206175316-206218047 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010525 Uncertain Supported Vesicles
Plasma membrane Mixed Tissue enhanced placenta: 11.2 esophagus: 5.5 GPR108 LUSTR2 ENSG00000125734 G protein-coupled receptor 108 19 6729914-6737603 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041924, HPA041951, HPA063863 Uncertain Supported Golgi apparatus
Vesicles Renal cancer:1.29e-9 (favourable), Endometrial cancer:1.04e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 73.7 GPR137 C11orf4, GPR137A, TM7SF1L1 ENSG00000173264 G protein-coupled receptor 137 11 64270062-64289500 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA062871 Uncertain Approved Nucleus
Nucleoli
Actin filaments Liver cancer:5.34e-4 (unfavourable), Pancreatic cancer:6.18e-4 (favourable) Expressed in all Expressed in all testis: 147.8 GPR137B TM7SF1 ENSG00000077585 G protein-coupled receptor 137B 1 236142505-236221865 Predicted membrane proteins, Transporters Evidence at protein level HPA026422 Approved Colorectal cancer:1.63e-4 (unfavourable) Expressed in all Mixed kidney: 70.2 GPR141 PGR13 ENSG00000187037 G protein-coupled receptor 141 7 37683796-37833788 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level Mixed Tissue enhanced bone marrow: 18.7 appendix: 5.8 GPR143 OA1 ENSG00000101850 G protein-coupled receptor 143 X 9725346-9786297 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA003648 Approved Renal cancer:2.45e-5 (favourable), Cervical cancer:8.73e-4 (favourable) Tissue enriched Mixed skin: 10.3 GPR160 GPCR1, GPCR150 ENSG00000173890 G protein-coupled receptor 160 3 170037929-170085403 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006970 Approved Supported Plasma membrane Renal cancer:4.93e-7 (favourable), Lung cancer:1.21e-4 (favourable), Urothelial cancer:3.61e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 426.5 small intestine: 111.2 GPR85 SREB2 ENSG00000164604 G protein-coupled receptor 85 7 113078331-113087778 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced cerebral cortex: 16.8 skeletal muscle: 11.5 GPRC5B RAIG-2 ENSG00000167191 G protein-coupled receptor, class C, group 5, member B 16 19856691-19886167 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015247 Approved Supported Nucleus
Nucleoli
Vesicles Colorectal cancer:9.27e-5 (unfavourable), Renal cancer:6.30e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 309.2 testis: 66.5 GPRC5C RAIG-3 ENSG00000170412 G protein-coupled receptor, class C, group 5, member C 17 74424851-74451653 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA029776 Supported Uncertain Nucleus
Microtubule organizing center
Cytosol Renal cancer:1.58e-5 (favourable) Expressed in all Mixed thyroid gland: 103.7 GPRC5D ENSG00000111291 G protein-coupled receptor, class C, group 5, member D 12 12940775-12952147 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA071909 Approved Head and neck cancer:5.09e-4 (favourable) Mixed Mixed testis: 5.2 GRIA1 GluA1, GLUR1, GLURA ENSG00000155511 Glutamate receptor, ionotropic, AMPA 1 5 153489615-153813869 FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB001965, HPA035202 Supported Tissue enriched Tissue enriched 6 cerebral cortex: 67.3 lung: 10.6 GRIA2 GluA2, GLUR2, GLURB ENSG00000120251 Glutamate receptor, ionotropic, AMPA 2 4 157204182-157366075 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB006830, CAB007812, HPA008441, CAB012981 Supported Group enriched Tissue enriched 8 cerebral cortex: 207.2 endometrium: 27.2 GRIA3 GluA3, GLUR3, GLURC, MRX94 ENSG00000125675 Glutamate receptor, ionotropic, AMPA 3 X 123184153-123490915 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA058659 Uncertain Tissue enriched Tissue enhanced cerebral cortex: 56.8 adrenal gland: 11.4 GRIA4 GluA4, GLUR4, GLURD ENSG00000152578 Glutamate receptor, ionotropic, AMPA 4 11 105609994-105982092 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Group enriched Tissue enriched 10 cerebral cortex: 73.4 adrenal gland: 7.4 GRID1 GluD1, KIAA1220 ENSG00000182771 Glutamate receptor, ionotropic, delta 1 10 85599555-86366493 Predicted membrane proteins Evidence at protein level Group enriched Tissue enhanced cerebral cortex: 7.7 thyroid gland: 3.4 GRID2 GluD2, GluR-delta-2 ENSG00000152208 Glutamate receptor, ionotropic, delta 2 4 92303622-93774556 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056253, HPA058538 Approved Tissue enriched Tissue enriched 10 testis: 59.7 cerebral cortex: 5.9 GRIK1 GluK1, GLUR5 ENSG00000171189 Glutamate receptor, ionotropic, kainate 1 21 29536933-29940033 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA014623 Uncertain Glioma:9.12e-4 (unfavourable) Group enriched Tissue enhanced adrenal gland: 16.8;cerebral cortex: 9.1 prostate: 3.9 GRIK2 GluK2, GLUR6, MRT6 ENSG00000164418 Glutamate receptor, ionotropic, kainate 2 6 101398788-102070083 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014395, HPA014623, CAB022463 Approved Tissue enhanced Tissue enhanced cerebral cortex: 22.6 thyroid gland: 6.2 GRIK3 GluK3, GLUR7 ENSG00000163873 Glutamate receptor, ionotropic, kainate 3 1 36795527-37034129 Plasma proteins, Predicted membrane proteins Evidence at protein level Tissue enhanced Tissue enriched 6 cerebral cortex: 19.8 seminal vesicle: 3.5 GRIK4 GluK4, GRIK, KA1 ENSG00000149403 Glutamate receptor, ionotropic, kainate 4 11 120511759-120988904 Predicted membrane proteins, Transporters Evidence at transcript level Tissue enriched Tissue enhanced cerebral cortex: 10.6 thyroid gland: 2.8 GRIK5 GluK5, GRIK2, KA2 ENSG00000105737 Glutamate receptor, ionotropic, kainate 5 19 41998321-42069498 Predicted membrane proteins Evidence at protein level Pancreatic cancer:7.23e-4 (favourable), Renal cancer:9.32e-4 (unfavourable) Tissue enhanced Tissue enhanced cerebral cortex: 30.9;parathyroid gland: 21.7 testis: 19.2 GRIN1 GluN1, NMDAR1 ENSG00000176884 Glutamate receptor, ionotropic, N-methyl D-aspartate 1 9 137138390-137168762 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters Evidence at protein level CAB006831 Approved Mixed Tissue enriched 202 cerebral cortex: 152.3 prostate: 0.7 GRIN2A GluN2A, NMDAR2A ENSG00000183454 Glutamate receptor, ionotropic, N-methyl D-aspartate 2A 16 9753404-10182754 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB022725 Supported Mixed Tissue enriched 5 cerebral cortex: 25.0 testis: 4.7 GRIN3A GluN3A ENSG00000198785 Glutamate receptor, ionotropic, N-methyl-D-aspartate 3A 9 101569353-101738580 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Tissue enriched Group enriched 5 cerebral cortex: 12.4;cervix, uterine: 2.5 seminal vesicle: 1.4 GRIN3B GluN3B ENSG00000116032 Glutamate receptor, ionotropic, N-methyl-D-aspartate 3B 19 1000419-1009732 FDA approved drug targets, Predicted membrane proteins Evidence at transcript level Mixed Tissue enhanced fallopian tube: 2.1;spleen: 1.2 lung: 0.7 GRINA HNRGW, LFG1, NMDARA1, TMBIM3 ENSG00000178719 Glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding) 8 143990058-143993415 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA036980, HPA036981 Approved Approved Nucleoli fibrillar center
Cytosol Expressed in all Expressed in all seminal vesicle: 261.5 GSG1 MGC3146 ENSG00000111305 Germ cell associated 1 12 13083560-13103683 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level Tissue enhanced Tissue enriched 364 testis: 571.3 duodenum: 1.5 GSG1L KTSR5831, MGC18079, PRO19651 ENSG00000169181 GSG1-like 16 27787535-28063509 Predicted membrane proteins, Transporters Evidence at protein level HPA014479 Approved Tissue enriched Tissue enhanced cerebral cortex: 11.7;heart muscle: 8.8 fallopian tube: 2.7 GSG1L2 ENSG00000214978 GSG1-like 2 17 9802386-9822071 Predicted membrane proteins Evidence at transcript level HPA059428 Uncertain Tissue enriched Group enriched 14 cerebral cortex: 1.5;testis: 1.1 all non-specific tissues: 0.0 HACD1 CAP, PTPLA ENSG00000165996 3-hydroxyacyl-CoA dehydratase 1 10 17589032-17617377 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Mixed Mixed heart muscle: 40.1 HCN1 BCNG-1, BCNG1, HAC-2 ENSG00000164588 Hyperpolarization activated cyclic nucleotide gated potassium channel 1 5 45254950-45696498 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA019195 Supported Not detected Tissue enriched 7 cerebral cortex: 11.5 heart muscle: 1.7 HEATR5A C14orf125, DKFZP434I1735 ENSG00000129493 HEAT repeat containing 5A 14 31291791-31420582 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA049539 Uncertain Renal cancer:1.11e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 17.9 HGSNAT FLJ32731, HGNAT, TMEM76 ENSG00000165102 Heparan-alpha-glucosaminide N-acetyltransferase 8 43140455-43202855 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA029578 Approved Ovarian cancer:6.33e-5 (favourable), Glioma:7.02e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 50.4 HIAT1 DKFZP564L0864 ENSG00000156875 Hippocampus abundant transcript 1 1 100038097-100083377 Predicted membrane proteins Evidence at transcript level HPA073681 Approved Vesicles Liver cancer:2.08e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 197.2 HLA-F ENSG00000204642 Major histocompatibility complex, class I, F 6 29722775-29738528 Plasma proteins, Predicted membrane proteins Evidence at protein level Renal cancer:2.67e-4 (unfavourable) Expressed in all Tissue enhanced lymph node: 40.6 duodenum: 28.3 HM13 dJ324O17.1, H13, IMP1, IMPAS, PSENL3, PSL3, SPP, SPPL1 ENSG00000101294 Histocompatibility (minor) 13 20 31514428-31577923 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA045089, HPA056062 Approved Supported Endoplasmic reticulum Renal cancer:4.64e-12 (unfavourable), Liver cancer:1.95e-5 (unfavourable) Expressed in all Expressed in all cervix, uterine: 153.3 HMGCR ENSG00000113161 3-hydroxy-3-methylglutaryl-CoA reductase 5 75336329-75362104 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008338, CAB016797 Approved Renal cancer:9.42e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 87.8 HTR2C 5-HT2C, 5HTR2C, HTR1C ENSG00000147246 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled X 114584078-114910061 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Tissue enhanced Tissue enriched 5 cerebral cortex: 3.1 cervix, uterine: 0.5 HVCN1 Hv1, MGC15619, VSOP ENSG00000122986 Hydrogen voltage gated channel 1 12 110627841-110704950 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039329 Approved Expressed in all Mixed testis: 82.3 IGSF1 IGCD1, IGDC1, INHBP, KIAA0364, MGC75490, PGSF2 ENSG00000147255 Immunoglobulin superfamily, member 1 X 131273506-131578899 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035582 Supported Approved Cytosol Endometrial cancer:4.25e-8 (unfavourable) Tissue enriched Tissue enhanced testis: 19.9 adrenal gland: 13.2 INSIG1 CL-6, MGC1405 ENSG00000186480 Insulin induced gene 1 7 155297776-155310235 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA071524 Approved Vesicles Thyroid cancer:9.62e-4 (unfavourable) Expressed in all Expressed in all liver: 281.1 ITPR1 ACV, Insp3r1, IP3R1, PPP1R94, SCA15, SCA16, SCA29 ENSG00000150995 Inositol 1,4,5-trisphosphate receptor, type 1 3 4493348-4847840 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA014765, HPA016487 Approved Approved Vesicles Thyroid cancer:3.43e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 104.9 thyroid gland: 47.2 KCNA2 HK4, Kv1.2 ENSG00000177301 Potassium channel, voltage gated shaker related subfamily A, member 2 1 110593580-110631474 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB001976 Supported Tissue enhanced Tissue enriched 5 cerebral cortex: 20.7 thyroid gland: 3.8 KCNJ12 hIRK1, IRK2, KCNJN1, Kir2.2, Kir2.2v ENSG00000184185 Potassium channel, inwardly rectifying subfamily J, member 12 17 21376197-21419872 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA027021 Approved Uncertain Nucleoplasm
Golgi apparatus
Cytosol Endometrial cancer:7.84e-5 (unfavourable) Mixed Group enriched 5 parathyroid gland: 18.9;skeletal muscle: 23.1 heart muscle: 3.9 KCNJ14 IRK4, Kir2.4 ENSG00000182324 Potassium channel, inwardly rectifying subfamily J, member 14 19 48455509-48466980 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA071765 Approved Nucleoli Mixed Mixed testis: 2.9 KCNJ18 KIR2.6, TTPP2 ENSG00000260458 Potassium channel, inwardly rectifying subfamily J, member 18 17 21692523-21704612 Disease related genes, Predicted membrane proteins Evidence at protein level HPA027021 Uncertain Uncertain Nucleoplasm
Golgi apparatus
Cytosol Tissue enhanced Group enriched 8 skin: 3.9;tonsil: 1.3 testis: 0.3 KCNK3 K2p3.1, TASK, TASK-1 ENSG00000171303 Potassium channel, two pore domain subfamily K, member 3 2 26692690-26733420 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Renal cancer:2.37e-7 (unfavourable) Tissue enhanced Tissue enhanced adrenal gland: 112.3;placenta: 35.5 lung: 19.9 KCNN4 hIKCa1, hKCa4, hSK4, IK, KCa3.1 ENSG00000104783 Potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 4 19 43766533-43781257 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA053841, HPA059622 Approved Renal cancer:1.05e-14 (unfavourable), Urothelial cancer:1.75e-4 (favourable), Glioma:3.77e-4 (unfavourable), Pancreatic cancer:4.56e-4 (unfavourable) Expressed in all Tissue enhanced salivary gland: 74.3 stomach: 37.1 KCNQ2 BFNC, EBN, EBN1, ENB1, HNSPC, KCNA11, Kv7.2 ENSG00000075043 Potassium channel, voltage gated KQT-like subfamily Q, member 2 20 63400210-63472677 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA016642, HPA057112 Approved Approved Endoplasmic reticulum Tissue enriched Tissue enriched 7 cerebral cortex: 56.3 adrenal gland: 8.2 KRTCAP3 KCP3 ENSG00000157992 Keratinocyte associated protein 3 2 27442366-27446481 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047136, HPA060203 Supported Approved Nucleus
Cytosol Breast cancer:2.67e-5 (favourable) Expressed in all Mixed small intestine: 35.5 LAPTM4B LC27 ENSG00000104341 Lysosomal protein transmembrane 4 beta 8 97775057-97853013 Predicted membrane proteins, Transporters Evidence at protein level CAB020782, HPA068830 Uncertain Approved Golgi apparatus Liver cancer:2.70e-6 (unfavourable), Breast cancer:5.63e-4 (unfavourable), Head and neck cancer:5.70e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 134.9 LEPROTL1 my047, Vps55 ENSG00000104660 Leptin receptor overlapping transcript-like 1 8 30095398-30177208 Predicted membrane proteins Evidence at protein level HPA047911 Uncertain Renal cancer:1.94e-5 (unfavourable), Colorectal cancer:9.04e-4 (favourable) Expressed in all Expressed in all placenta: 119.4 LHFP MGC22429 ENSG00000183722 Lipoma HMGIC fusion partner 13 39342892-39603528 Cancer-related genes, Disease related genes, Predicted membrane proteins Evidence at protein level HPA058975 Approved Approved Nucleoli Renal cancer:1.20e-7 (unfavourable), Urothelial cancer:2.30e-4 (unfavourable) Expressed in all Mixed placenta: 195.0 LHFPL1 ENSG00000182508 Lipoma HMGIC fusion partner-like 1 X 112630648-112680054 Predicted membrane proteins Evidence at transcript level HPA003029 Uncertain Mixed Tissue enhanced cerebral cortex: 1.8 seminal vesicle: 1.3 LHFPL2 KIAA0206 ENSG00000145685 Lipoma HMGIC fusion partner-like 2 5 78485215-78770021 Predicted membrane proteins Evidence at protein level HPA042402 Uncertain Approved Vesicles
Actin filaments Renal cancer:3.45e-7 (unfavourable), Liver cancer:2.73e-4 (unfavourable) Expressed in all Mixed gallbladder: 36.4 LIM2 MP17, MP19 ENSG00000105370 Lens intrinsic membrane protein 2, 19kDa 19 51379909-51387960 Disease related genes, Predicted membrane proteins Evidence at protein level Tissue enriched Not detected testis: 0.4 LMBR1L FLJ10494, KIAA1174 ENSG00000139636 Limb development membrane protein 1-like 12 49096551-49110900 Predicted membrane proteins Evidence at protein level Renal cancer:4.45e-7 (unfavourable), Colorectal cancer:1.04e-4 (unfavourable), Pancreatic cancer:3.50e-4 (favourable) Expressed in all Tissue enhanced testis: 27.5 endometrium: 9.0 LMF1 C16orf26, FLJ12681, FLJ22302, JFP11, TMEM112, TMEM112A ENSG00000103227 Lipase maturation factor 1 16 853634-981318 Disease related genes, Predicted membrane proteins Evidence at protein level Renal cancer:7.95e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 22.7 LTB4R BLTR, CMKRL1, GPR16, LTB4R1, P2RY7, P2Y7 ENSG00000213903 Leukotriene B4 receptor 14 24311450-24318036 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA003873 Approved Renal cancer:3.44e-15 (unfavourable), Pancreatic cancer:1.85e-4 (favourable) Expressed in all Tissue enhanced skin: 165.5 esophagus: 42.8 MAL ENSG00000172005 Mal, T-cell differentiation protein 2 95025677-95053996 Predicted membrane proteins Evidence at protein level HPA065691 Approved Centrosome Renal cancer:3.96e-9 (favourable), Endometrial cancer:5.18e-6 (unfavourable) Mixed Tissue enriched 7 esophagus: 2459.4 tonsil: 328.8 MBOAT2 FLJ14415, FLJ90298, OACT2 ENSG00000143797 Membrane bound O-acyltransferase domain containing 2 2 8852690-9003813 Enzymes, Predicted membrane proteins Evidence at protein level HPA014836 Uncertain Approved Vesicles Endometrial cancer:2.13e-9 (unfavourable), Urothelial cancer:5.32e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 49.4 cerebral cortex: 29.8 MBOAT7 BB1, hMBOA-7, LENG4, LPIAT ENSG00000125505 Membrane bound O-acyltransferase domain containing 7 19 54173412-54189882 Enzymes, Predicted membrane proteins Evidence at protein level HPA055967 Approved Approved Cytosol Liver cancer:5.55e-6 (unfavourable), Renal cancer:6.62e-5 (unfavourable), Urothelial cancer:4.31e-4 (favourable), Lung cancer:5.13e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 24.3 MC2R ACTHR ENSG00000185231 Melanocortin 2 receptor (adrenocorticotropic hormone) 18 13882044-13915707 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level Not detected Tissue enriched 24 adrenal gland: 50.8 epididymis: 2.1 MFSD6 FLJ20160 ENSG00000151690 Major facilitator superfamily domain containing 6 2 190408355-190509205 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA022274 Approved Approved Nucleoplasm
Actin filaments
Cytosol Renal cancer:1.05e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 79.2 MGST3 GST-III ENSG00000143198 Microsomal glutathione S-transferase 3 1 165630861-165661796 Enzymes, Predicted membrane proteins Evidence at protein level HPA053311 Approved Nucleus Expressed in all Expressed in all epididymis: 621.5 MPDU1 CDGIf, Lec35, PQLC5, SL15 ENSG00000129255 Mannose-P-dolichol utilization defect 1 17 7583529-7592789 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014845 Uncertain Supported Endoplasmic reticulum
Mitochondria Expressed in all Expressed in all rectum: 70.2 MPV17 SYM1 ENSG00000115204 MpV17 mitochondrial inner membrane protein 2 27309492-27325680 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Liver cancer:6.99e-6 (unfavourable) Expressed in all Expressed in all thyroid gland: 84.1 MS4A1 B1, Bp35, CD20, MS4A2 ENSG00000156738 Membrane-spanning 4-domains, subfamily A, member 1 11 60455752-60470760 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB000015, HPA014341, HPA014391 Supported Breast cancer:4.34e-5 (favourable) Mixed Group enriched 15 appendix: 249.3;lymph node: 780.6;spleen: 476.2;tonsil: 821.5 urinary bladder: 39.8 MS4A13 ENSG00000204979 Membrane-spanning 4-domains, subfamily A, member 13 11 60515413-60542721 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA045017, HPA063626 Uncertain Not detected Tissue enriched 54 testis: 5.3 all non-specific tissues: 0.0 MS4A14 DKFZp434H092, FLJ32856, MS4A16, NYD-SP21 ENSG00000166928 Membrane-spanning 4-domains, subfamily A, member 14 11 60378530-60417756 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at transcript level Mixed Tissue enriched 12 testis: 91.2 spleen: 7.7 MS4A15 ENSG00000166961 Membrane-spanning 4-domains, subfamily A, member 15 11 60756953-60776732 Predicted membrane proteins Evidence at transcript level Tissue enhanced Tissue enriched 11 lung: 71.5 endometrium: 6.2 MS4A4A CD20L1, MS4A4, MS4A7 ENSG00000110079 Membrane-spanning 4-domains, subfamily A, member 4A 11 60280541-60308972 Predicted membrane proteins Evidence at transcript level HPA029323 Approved Expressed in all Tissue enhanced placenta: 101.4 adipose tissue: 62.8 MS4A4E ENSG00000214787 Membrane-spanning 4-domains, subfamily A, member 4E 11 60201253-60243088 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040075 Uncertain Mixed Mixed adipose tissue,gallbladder: 5.8 MS4A5 CD20L2 ENSG00000166930 Membrane-spanning 4-domains, subfamily A, member 5 11 60429589-60455214 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA043732 Uncertain Not detected Tissue enriched 270 testis: 72.6 duodenum: 0.2 MS4A6A CD20L3, MS4A6 ENSG00000110077 Membrane-spanning 4-domains, subfamily A, member 6A 11 60172014-60184666 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA011391, HPA076623 Approved Approved Vesicles Cervical cancer:6.33e-4 (favourable) Expressed in all Expressed in all lymph node: 115.2 MS4A8 CD20L5, MS4A4, MS4A8B ENSG00000166959 Membrane-spanning 4-domains, subfamily A, member 8 11 60699574-60715811 Predicted membrane proteins Evidence at protein level HPA007318, HPA007319 Supported Tissue enhanced Tissue enhanced duodenum: 191.8;fallopian tube: 223.5;small intestine: 215.2 stomach: 49.6 MT-ND3 MTND3, NAD3, ND3 ENSG00000198840 Mitochondrially encoded NADH dehydrogenase 3 MT 10059-10404 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA063296 Supported Approved Cytosol Liver cancer:4.63e-5 (favourable) Expressed in all Expressed in all heart muscle: 30137.8 MTCH1 CGI-64, PSAP, SLC25A49 ENSG00000137409 Mitochondrial carrier 1 6 36968141-36986298 Predicted membrane proteins, Transporters Evidence at protein level HPA015971 Approved Renal cancer:1.16e-7 (favourable), Liver cancer:1.17e-4 (unfavourable), Endometrial cancer:2.06e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 568.7 MYADM ENSG00000179820 Myeloid-associated differentiation marker 19 53866223-53876437 Predicted membrane proteins, Transporters Evidence at protein level HPA056301 Approved Nuclear speckles Renal cancer:7.71e-7 (unfavourable), Lung cancer:8.15e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 257.6 NDFIP1 MGC10924, N4WBP5 ENSG00000131507 Nedd4 family interacting protein 1 5 142108505-142154443 Predicted membrane proteins Evidence at protein level HPA009682 Approved Head and neck cancer:2.33e-7 (unfavourable), Renal cancer:2.39e-7 (favourable) Expressed in all Expressed in all cerebral cortex: 246.7 NDFIP2 KIAA1165, N4wbp5a ENSG00000102471 Nedd4 family interacting protein 2 13 79481124-79556075 Predicted membrane proteins Evidence at protein level HPA009160 Uncertain Validated Vesicles Renal cancer:4.18e-5 (favourable), Head and neck cancer:5.99e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 96.3 NDUFA11 B14.7 ENSG00000174886 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 11, 14.7kDa 19 5891276-5904006 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA072209 Uncertain Mitochondria Endometrial cancer:3.38e-5 (favourable), Cervical cancer:4.54e-5 (favourable) Expressed in all Expressed in all heart muscle: 298.5 NKAIN1 FAM77C, FLJ12650 ENSG00000084628 Na+/K+ transporting ATPase interacting 1 1 31179745-31239554 Predicted membrane proteins Evidence at transcript level HPA006873 Uncertain Group enriched Tissue enhanced adrenal gland: 13.9;cerebral cortex: 13.1;skeletal muscle: 7.4 epididymis: 4.4 NKAIN2 FAM77B, TCBA1 ENSG00000188580 Na+/K+ transporting ATPase interacting 2 6 123804141-124825657 Disease related genes, Predicted membrane proteins Evidence at transcript level HPA045860 Approved Cytosol Mixed Tissue enriched 44 cerebral cortex: 48.0 adipose tissue,skeletal muscle,testis: 1.0 NKAIN3 FAM77D, FLJ39630 ENSG00000185942 Na+/K+ transporting ATPase interacting 3 8 62248591-62999652 Predicted membrane proteins Evidence at transcript level HPA018833 Uncertain Tissue enhanced Not detected adrenal gland: 0.4 NKAIN4 bA261N11.2, C20orf58, FAM77A ENSG00000101198 Na+/K+ transporting ATPase interacting 4 20 63240784-63272694 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA029876 Approved Endometrial cancer:3.14e-4 (unfavourable) Tissue enriched Tissue enriched 13 cerebral cortex: 71.9 kidney: 5.5 NKG7 GIG1, GMP-17 ENSG00000105374 Natural killer cell granule protein 7 19 51371606-51372715 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA071454 Approved Vesicles Renal cancer:3.32e-6 (unfavourable), Endometrial cancer:7.42e-6 (favourable) Expressed in all Tissue enhanced bone marrow: 352.2;spleen: 153.8 lymph node: 124.8 NOX4 KOX, KOX-1 ENSG00000086991 NADPH oxidase 4 11 89324356-89498187 Predicted membrane proteins, Transporters Evidence at protein level HPA015475 Uncertain Approved Nucleus Renal cancer:6.14e-4 (favourable) Mixed Tissue enriched 12 kidney: 133.6 parathyroid gland: 10.7 NRM NRM29 ENSG00000137404 Nurim (nuclear envelope membrane protein) 6 30688047-30691420 Predicted membrane proteins Evidence at protein level HPA072545, HPA073982 Validated Nuclear membrane Renal cancer:3.52e-8 (unfavourable) Expressed in all Mixed skin: 1.6 ODF4 CT136, OPPO1 ENSG00000184650 Outer dense fiber of sperm tails 4 17 8339864-8346046 Predicted membrane proteins Evidence at protein level Not detected Tissue enriched 56 testis: 21.1 esophagus: 0.3 OMA1 FLJ33782, MPRP-1, YKR087C, ZMPOMA1 ENSG00000162600 OMA1 zinc metallopeptidase 1 58415384-58546802 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055120 Approved Approved Nucleoplasm
Mitochondria Breast cancer:1.63e-4 (favourable), Colorectal cancer:7.70e-4 (favourable), Lung cancer:8.52e-4 (favourable) Expressed in all Expressed in all prostate: 32.2 OR4N2 ENSG00000176294 Olfactory receptor, family 4, subfamily N, member 2 14 19719015-19828372 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level Not detected Tissue enriched 15 testis: 26.7 cerebral cortex: 1.7 ORAI1 CRACM1, FLJ14466, TMEM142A ENSG00000276045 ORAI calcium release-activated calcium modulator 1 12 121626550-121642677 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA016583, HPA061823 Approved Supported Cytosol Ovarian cancer:4.30e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 48.9 ORAI2 C7orf19, CBCIP2, FLJ12474, FLJ14733, H_NH0514P08.8, TMEM142B ENSG00000160991 ORAI calcium release-activated calcium modulator 2 7 102433106-102456821 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055137, HPA065937 Uncertain Approved Nucleus Pancreatic cancer:8.49e-5 (favourable), Thyroid cancer:6.65e-4 (favourable) Expressed in all Mixed appendix: 43.3 ORAI3 MGC13024, TMEM142C ENSG00000175938 ORAI calcium release-activated calcium modulator 3 16 30949066-30956461 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015022 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:3.87e-5 (unfavourable) Expressed in all Expressed in all prostate: 26.7 ORMDL1 ENSG00000128699 ORMDL sphingolipid biosynthesis regulator 1 2 189770323-189784371 Predicted membrane proteins Evidence at protein level HPA065643 Supported Endoplasmic reticulum Renal cancer:5.84e-9 (unfavourable), Urothelial cancer:1.49e-5 (favourable), Ovarian cancer:3.04e-5 (favourable) Expressed in all Expressed in all epididymis: 153.1 ORMDL3 ENSG00000172057 ORMDL sphingolipid biosynthesis regulator 3 17 39921041-39927601 Disease related genes, Predicted membrane proteins Evidence at protein level HPA065643 Supported Endoplasmic reticulum Urothelial cancer:5.18e-4 (favourable), Lung cancer:9.29e-4 (favourable) Expressed in all Expressed in all adipose tissue: 165.1 OSTC DC2 ENSG00000198856 Oligosaccharyltransferase complex subunit (non-catalytic) 4 108650584-108667820 Predicted membrane proteins Evidence at protein level HPA065174 Approved Nucleoplasm Renal cancer:2.31e-8 (unfavourable), Endometrial cancer:1.44e-4 (favourable), Lung cancer:2.84e-4 (unfavourable), Head and neck cancer:6.66e-4 (unfavourable) Expressed in all Expressed in all epididymis: 211.5 P2RY6 P2Y6 ENSG00000171631 Pyrimidinergic receptor P2Y, G-protein coupled, 6 11 73264505-73298617 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022740 Uncertain Renal cancer:2.50e-7 (unfavourable) Mixed Tissue enhanced placenta: 16.8;spleen: 36.2 appendix: 11.0 PAQR6 FLJ22672, PRdelta ENSG00000160781 Progestin and adipoQ receptor family member VI 1 156243321-156248117 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA073505 Approved Nucleus
Nucleoli Renal cancer:1.58e-8 (unfavourable), Colorectal cancer:1.60e-5 (unfavourable), Urothelial cancer:1.86e-4 (favourable), Prostate cancer:1.99e-4 (unfavourable) Tissue enriched Tissue enriched 9 cerebral cortex: 97.8 skin: 10.8 PAQR9 FLJ41938 ENSG00000188582 Progestin and adipoQ receptor family member IX 3 142949164-142963682 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052798 Uncertain Tissue enriched Tissue enhanced liver: 8.3;testis: 19.3 heart muscle: 5.2 PARL PRO2207, PSARL, PSARL1, RHBDS1 ENSG00000175193 Presenilin associated, rhomboid-like 3 183829385-183884933 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA019545 Approved Supported Mitochondria Urothelial cancer:9.11e-5 (favourable) Expressed in all Expressed in all epididymis: 71.5 PCDHA9 KIAA0345, PCDH-ALPHA9 ENSG00000204961 Protocadherin alpha 9 5 140847463-141012344 Plasma proteins, Predicted membrane proteins Evidence at transcript level Not detected Tissue enhanced testis: 1.6 cerebral cortex: 0.6 PEMT PEMPT, PEMT2 ENSG00000133027 Phosphatidylethanolamine N-methyltransferase 17 17505563-17591708 Enzymes, Predicted membrane proteins Evidence at protein level HPA042375 Approved Approved Cytosol Endometrial cancer:6.77e-6 (favourable) Expressed in all Expressed in all epididymis: 205.4 PERP dJ496H19.1, KCP1, KRTCAP1, PIGPC1, THW ENSG00000112378 PERP, TP53 apoptosis effector 6 138088505-138107511 Predicted membrane proteins Evidence at protein level HPA022269 Supported Pancreatic cancer:1.05e-5 (unfavourable), Lung cancer:3.73e-4 (unfavourable), Breast cancer:5.46e-4 (unfavourable) Expressed in all Group enriched 6 esophagus: 574.1;skin: 1238.6 breast: 149.6 PEX11A MGC119947, MGC138534, PEX11-ALPHA ENSG00000166821 Peroxisomal biogenesis factor 11 alpha 15 89677764-89690783 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Head and neck cancer:2.57e-4 (unfavourable) Expressed in all Mixed prostate: 29.0 PGAP1 Bst1, FLJ12377, SPG67 ENSG00000197121 Post-GPI attachment to proteins 1 2 196833004-196927796 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA069704 Uncertain Mixed Mixed skin: 14.7 PGAP2 CWH43-N, FRAG1, MRT21 ENSG00000148985 Post-GPI attachment to proteins 2 11 3797724-3826371 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA063099 Approved Approved Microtubules Liver cancer:7.49e-4 (unfavourable) Expressed in all Expressed in all epididymis: 258.9 PHTF2 DKFZp434D166 ENSG00000006576 Putative homeodomain transcription factor 2 7 77798792-77957503 Predicted membrane proteins, Transcription factors Evidence at protein level HPA012312 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:3.09e-7 (unfavourable), Thyroid cancer:2.78e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 60.8 PIEZO1 FAM38A, KIAA0233 ENSG00000103335 Piezo-type mechanosensitive ion channel component 1 16 88715343-88785211 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA047185 Uncertain Renal cancer:8.89e-7 (unfavourable), Lung cancer:2.36e-5 (unfavourable), Cervical cancer:2.37e-4 (unfavourable), Ovarian cancer:3.78e-4 (unfavourable) Expressed in all Mixed adipose tissue: 42.0 PIGV FLJ20477 ENSG00000060642 Phosphatidylinositol glycan anchor biosynthesis, class V 1 26787472-26798398 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054181 Approved Endoplasmic reticulum
Cytosol Renal cancer:7.60e-7 (favourable) Expressed in all Expressed in all testis: 83.5 PKD1 PBP, Pc-1, TRPP1 ENSG00000008710 Polycystic kidney disease 1 (autosomal dominant) 16 2088710-2135898 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB046448 Approved Pancreatic cancer:3.38e-5 (favourable), Head and neck cancer:3.35e-4 (favourable), Colorectal cancer:7.43e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 21.6 PLLP PMLP, TM4SF11 ENSG00000102934 Plasmolipin 16 57248547-57284687 Predicted membrane proteins Evidence at protein level HPA041862 Supported Renal cancer:6.21e-9 (favourable), Endometrial cancer:2.80e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 118.4 PLP2 A4, A4-LSB, MGC126187 ENSG00000102007 Proteolipid protein 2 (colonic epithelium-enriched) X 49171926-49175239 Predicted membrane proteins, Transporters Evidence at protein level HPA042415 Approved Renal cancer:5.55e-10 (unfavourable), Endometrial cancer:3.32e-5 (unfavourable) Expressed in all Expressed in all skin: 480.7 PLPP2 LPP2, PAP-2c, PPAP2C ENSG00000141934 Phospholipid phosphatase 2 19 281040-291504 Enzymes, Predicted membrane proteins Evidence at protein level HPA055540 Uncertain Approved Mitochondria Endometrial cancer:3.21e-8 (favourable), Breast cancer:4.55e-4 (unfavourable) Expressed in all Tissue enhanced fallopian tube: 126.8 cervix, uterine: 91.2 PLPP5 DPPL1, HTPAP, PPAPDC1B ENSG00000147535 Phospholipid phosphatase 5 8 38263130-38269243 Enzymes, Predicted membrane proteins Evidence at protein level HPA055777 Approved Vesicles Renal cancer:8.33e-10 (unfavourable), Endometrial cancer:1.48e-5 (favourable), Ovarian cancer:2.42e-5 (favourable), Lung cancer:8.72e-5 (favourable) Expressed in all Expressed in all prostate: 123.7 PLPP6 FLJ46512, FLJ90191, PDP1, PPAPDC2 ENSG00000205808 Phospholipid phosphatase 6 9 4662315-4665258 Predicted membrane proteins Evidence at protein level HPA018096 Approved Approved Nucleoplasm
Vesicles Renal cancer:3.99e-4 (favourable) Expressed in all Mixed prostate: 26.8 PMP22 GAS3, HNPP, Sp110 ENSG00000109099 Peripheral myelin protein 22 17 15229777-15265326 Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:1.73e-4 (unfavourable) Expressed in all Expressed in all placenta,small intestine: 314.4 POMT2 LGMD2N ENSG00000009830 Protein-O-mannosyltransferase 2 14 77274956-77320884 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA003663 Uncertain Liver cancer:2.40e-4 (unfavourable) Expressed in all Expressed in all testis: 28.8 POPDC2 POP2 ENSG00000121577 Popeye domain containing 2 3 119636457-119665324 Predicted membrane proteins Evidence at protein level HPA024255 Supported Mixed Tissue enhanced heart muscle: 191.4;seminal vesicle: 63.4 smooth muscle: 35.0 PQLC1 FLJ22378 ENSG00000122490 PQ loop repeat containing 1 18 79902420-79951664 Predicted membrane proteins Evidence at protein level HPA051666 Uncertain Approved Nucleoplasm Expressed in all Expressed in all adipose tissue: 40.5 PQLC2 FLJ20320 ENSG00000040487 PQ loop repeat containing 2 1 19312326-19329300 Predicted membrane proteins, Transporters Evidence at protein level HPA057810 Approved Validated Vesicles Liver cancer:2.64e-5 (unfavourable), Endometrial cancer:3.50e-4 (favourable) Expressed in all Expressed in all testis: 16.3 PQLC3 C2orf22, MGC33602 ENSG00000162976 PQ loop repeat containing 3 2 11155198-11178874 Predicted membrane proteins Evidence at protein level HPA061607 Approved Cytosol Expressed in all Expressed in all cervix, uterine: 54.2 PRAF2 JM4 ENSG00000243279 PRA1 domain family, member 2 X 49071156-49074071 Predicted membrane proteins Evidence at protein level HPA002859, HPA005504, CAB011655 Supported Approved Endoplasmic reticulum
Vesicles Liver cancer:1.66e-6 (unfavourable), Pancreatic cancer:4.88e-6 (favourable), Renal cancer:5.83e-6 (unfavourable), Lung cancer:2.81e-4 (favourable), Cervical cancer:7.42e-4 (favourable) Expressed in all Expressed in all epididymis: 181.8 PSEN1 AD3, FAD, PS1, S182 ENSG00000080815 Presenilin 1 14 73136418-73223691 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB006844, HPA030760, HPA067496 Approved Approved Nucleus
Golgi apparatus
Cell Junctions Renal cancer:1.52e-8 (favourable), Liver cancer:1.99e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 66.1 PSEN2 AD3L, AD4, PS2, STM2 ENSG00000143801 Presenilin 2 1 226870184-226896105 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB013634, HPA038005 Supported Nucleus Expressed in all Expressed in all parathyroid gland: 29.1 PTCH1 BCNS, NBCCS, PTCH ENSG00000185920 Patched 1 9 95442980-95517057 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB013717, HPA075072 Uncertain Approved Golgi apparatus Mixed Tissue enhanced cervix, uterine: 41.6 endometrium: 27.2 PTCHD1 FLJ30296 ENSG00000165186 Patched domain containing 1 X 23334015-23404372 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA046110 Uncertain Mixed Tissue enhanced epididymis: 9.6 seminal vesicle: 5.3 PTCHD4 C6orf138, dJ402H5.2, FLJ41841 ENSG00000244694 Patched domain containing 4 6 47878028-48068689 Predicted membrane proteins Evidence at transcript level HPA041276 Uncertain Approved Plasma membrane
Cytosol Renal cancer:1.49e-6 (favourable) Group enriched Mixed seminal vesicle: 2.8 PTGES MGST-IV, MGST1-L1, MGST1L1, PIG12, TP53I12 ENSG00000148344 Prostaglandin E synthase 9 129738331-129753047 Enzymes, Predicted membrane proteins Evidence at protein level HPA045064 Supported Supported Endoplasmic reticulum Pancreatic cancer:7.97e-5 (unfavourable), Colorectal cancer:2.32e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 82.2;seminal vesicle: 118.1 urinary bladder: 37.5 RCE1 FACE-2, FACE2, hRCE1, RCE1A, RCE1B ENSG00000173653 Ras converting CAAX endopeptidase 1 11 66842835-66846546 Enzymes, Predicted membrane proteins Evidence at protein level Expressed in all Mixed skin: 23.4 REEP1 C2orf23, FLJ13110, SPG31 ENSG00000068615 Receptor accessory protein 1 2 86213993-86338083 Disease related genes, Predicted membrane proteins Evidence at protein level HPA058061 Approved Mixed Tissue enhanced cerebral cortex: 54.2;testis: 90.8 smooth muscle: 34.1 REEP3 C10orf74 ENSG00000165476 Receptor accessory protein 3 10 63521363-63625123 Predicted membrane proteins Evidence at protein level Pancreatic cancer:1.32e-4 (unfavourable), Liver cancer:3.19e-4 (unfavourable), Head and neck cancer:7.83e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 55.8 RER1 ENSG00000157916 Retention in endoplasmic reticulum sorting receptor 1 1 2391775-2405444 Predicted membrane proteins, Transporters Evidence at protein level CAB037240, HPA051400 Supported Validated Golgi apparatus Renal cancer:8.23e-8 (unfavourable) Expressed in all Expressed in all testis: 183.8 RHBDD1 DKFZp547E052 ENSG00000144468 Rhomboid domain containing 1 2 226835581-226999215 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA013972, HPA057125 Approved Supported Endoplasmic reticulum Expressed in all Expressed in all testis: 32.2 RNF103 hkf-1, KF1, ZFP103 ENSG00000239305 Ring finger protein 103 2 86603393-86623866 Predicted membrane proteins Evidence at protein level HPA057922 Approved Urothelial cancer:6.77e-5 (favourable) Expressed in all Expressed in all epididymis: 54.2 RNF170 ADSA, DKFZP564A022, SNAX1 ENSG00000120925 Ring finger protein 170 8 42849637-42897290 Disease related genes, Predicted membrane proteins Evidence at protein level HPA050931, HPA054621 Uncertain Expressed in all Expressed in all thyroid gland: 47.6 RNF175 FLJ34190 ENSG00000145428 Ring finger protein 175 4 153710125-153760235 Predicted membrane proteins Evidence at protein level HPA035837 Uncertain Glioma:4.15e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 13.2 seminal vesicle: 4.8 RNF213 C17orf27, KIAA1554, KIAA1618, MYMY2, NET57 ENSG00000173821 Ring finger protein 213 17 80260866-80398786 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003347, HPA026790 Approved Supported Cytosol Endometrial cancer:4.65e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 66.8 RNFT2 FLJ14627, TMEM118 ENSG00000135119 Ring finger protein, transmembrane 2 12 116738178-116853631 Predicted membrane proteins Evidence at protein level HPA064161 Approved Approved Nucleoplasm
Cytosol Mixed Tissue enhanced cerebral cortex: 15.4 testis: 6.1 RP11-872D17.8 ENSG00000254979 11 57387365-57424059 Predicted membrane proteins Evidence at protein level HPA038515 Supported Mixed Tissue enhanced bone marrow: 7.8;placenta: 10.5 skin: 5.8 RPN2 RIBIIR, RPN-II, RPNII, SWP1 ENSG00000118705 Ribophorin II 20 37178410-37241623 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008297, CAB019277, HPA025922 Supported Supported Endoplasmic reticulum Renal cancer:1.44e-10 (unfavourable), Liver cancer:1.38e-4 (unfavourable), Urothelial cancer:2.44e-4 (unfavourable) Expressed in all Expressed in all epididymis: 358.1 S1PR5 Edg-8, EDG8 ENSG00000180739 Sphingosine-1-phosphate receptor 5 19 10512742-10517931 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029683 Supported Renal cancer:6.71e-7 (unfavourable) Group enriched Tissue enhanced cerebral cortex: 14.9;skin: 22.1 spleen: 12.2 SACM1L KIAA0851, SAC1 ENSG00000211456 SAC1 suppressor of actin mutations 1-like (yeast) 3 45689056-45745424 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039573, HPA069869 Approved Approved Nucleoplasm
Golgi apparatus Renal cancer:5.47e-7 (favourable) Expressed in all Expressed in all thyroid gland: 67.2 SAMD8 FLJ25082, SMSr ENSG00000156671 Sterile alpha motif domain containing 8 10 75099586-75182123 Predicted membrane proteins Evidence at protein level HPA044402 Supported Endoplasmic reticulum Expressed in all Expressed in all cerebral cortex: 43.2 SC5D SC5DL ENSG00000109929 Sterol-C5-desaturase 11 121292453-121308694 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA066283, HPA070248 Approved Approved Nucleoplasm
Endoplasmic reticulum
Plasma membrane
Cytosol Renal cancer:1.07e-7 (favourable), Head and neck cancer:3.30e-4 (unfavourable), Melanoma:3.98e-4 (unfavourable) Expressed in all Expressed in all liver: 193.1 SCAMP1 SCAMP37 ENSG00000085365 Secretory carrier membrane protein 1 5 78360583-78479071 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044753 Approved Nucleoplasm
Vesicles
Cell Junctions Renal cancer:1.92e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 69.4 SCAMP4 FLJ33847 ENSG00000227500 Secretory carrier membrane protein 4 19 1905214-1926013 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043284 Approved Approved Golgi apparatus
Vesicles
Lipid droplets
Plasma membrane Endometrial cancer:4.40e-6 (favourable), Liver cancer:1.92e-5 (unfavourable), Renal cancer:3.56e-4 (favourable) Expressed in all Expressed in all fallopian tube: 58.6 SCAMP5 MGC24969 ENSG00000198794 Secretory carrier membrane protein 5 15 74957219-75021496 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046645 Approved Renal cancer:1.34e-6 (favourable), Pancreatic cancer:5.67e-5 (favourable) Expressed in all Tissue enhanced cerebral cortex: 276.3 parathyroid gland: 80.7 SCN2A HBSCI, HBSCII, Nav1.2, SCN2A1, SCN2A2 ENSG00000136531 Sodium channel, voltage gated, type II alpha subunit 2 165239402-165392310 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB022567 Supported Tissue enhanced Tissue enriched 22 cerebral cortex: 58.5 kidney: 2.7 SCN5A CDCD2, CMD1E, CMPD2, HB1, HB2, HBBD, HH1, ICCD, IVF, LQT3, Nav1.5, PFHB1, SSS1 ENSG00000183873 Sodium channel, voltage gated, type V alpha subunit 3 38548057-38649673 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Mixed Tissue enriched 18 heart muscle: 26.9 cervix, uterine: 1.5 SDHC CYB560, PGL3 ENSG00000143252 Succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa 1 161314257-161375340 Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Renal cancer:2.20e-4 (favourable) Expressed in all Expressed in all kidney: 187.3 SEC22A SEC22L2 ENSG00000121542 SEC22 homolog A, vesicle trafficking protein 3 123201927-123274130 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Renal cancer:2.48e-4 (unfavourable) Expressed in all Expressed in all testis: 48.4 SEC61A2 FLJ10578 ENSG00000065665 Sec61 translocon alpha 2 subunit 10 12129637-12169961 Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:2.22e-16 (unfavourable), Pancreatic cancer:1.08e-5 (favourable), Urothelial cancer:8.75e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 51.4 testis: 32.3 SEC63 DNAJC23, ERdj2, PRO2507, SEC63L ENSG00000025796 SEC63 homolog, protein translocation regulator 6 107867756-107958189 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA053295, HPA060535 Supported Supported Endoplasmic reticulum Breast cancer:3.32e-4 (unfavourable), Cervical cancer:4.01e-4 (unfavourable), Renal cancer:6.16e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 87.1 SEL1L3 KIAA0746 ENSG00000091490 Sel-1 suppressor of lin-12-like 3 (C. elegans) 4 25747427-25863760 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040045, HPA058792 Approved Validated Nucleus Urothelial cancer:4.33e-4 (favourable) Expressed in all Expressed in all lymph node: 148.5 SEPP1 SelP, SeP, SEPP ENSG00000250722 Selenoprotein P, plasma, 1 5 42799880-42887392 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA036287 Approved Approved Nucleus
Golgi apparatus Renal cancer:6.97e-6 (favourable) Expressed in all Expressed in all liver: 2937.1 SERINC3 AIGP1, DIFF33, SBBI99, TDE, TDE1, TMS-1 ENSG00000132824 Serine incorporator 3 20 44496221-44522109 Predicted membrane proteins Evidence at protein level HPA048116 Uncertain Cervical cancer:1.01e-4 (unfavourable) Expressed in all Expressed in all testis: 200.8 SFT2D3 MGC5391 ENSG00000173349 SFT2 domain containing 3 2 127701508-127705242 Predicted membrane proteins Evidence at protein level Not detected Not detected epididymis: 0.8 SGMS1 MGC17342, MOB, SMS1, TMEM23 ENSG00000198964 Sphingomyelin synthase 1 10 50305586-50625163 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045191 Approved Approved Nucleoplasm
Cytosol Renal cancer:1.95e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 114.4 SGMS2 MGC26963, SMS2 ENSG00000164023 Sphingomyelin synthase 2 4 107824563-107915047 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015076 Supported Renal cancer:1.37e-4 (favourable) Expressed in all Mixed gallbladder: 64.5 SIDT2 CGI-40 ENSG00000149577 SID1 transmembrane family, member 2 11 117178733-117197445 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA052352 Approved Renal cancer:4.18e-5 (unfavourable) Expressed in all Expressed in all prostate: 59.7 SLC11A2 DCT1, DMT1, NRAMP2 ENSG00000110911 Solute carrier family 11 (proton-coupled divalent metal ion transporter), member 2 12 50979401-51028566 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA032139, HPA032140 Uncertain Supported Mitochondria Lung cancer:3.07e-6 (favourable) Expressed in all Expressed in all thyroid gland: 74.8 SLC12A1 NKCC2 ENSG00000074803 Solute carrier family 12 (sodium/potassium/chloride transporter), member 1 15 48191664-48304078 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA014967, HPA018107 Supported Tissue enhanced Tissue enriched 456 kidney: 773.2 testis: 1.6 SLC12A5 KCC2, KIAA1176 ENSG00000124140 Solute carrier family 12 (potassium/chloride transporter), member 5 20 46021690-46060152 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA072058 Supported Glioma:8.45e-4 (unfavourable) Mixed Tissue enriched 8 cerebral cortex: 94.5 adrenal gland: 12.0 SLC12A8 CCC9 ENSG00000221955 Solute carrier family 12, member 8 3 125082636-125212864 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA031123 Uncertain Supported Nucleoplasm Renal cancer:5.56e-4 (unfavourable) Expressed in all Tissue enhanced thyroid gland: 39.4 gallbladder: 16.3 SLC12A9 CIP1 ENSG00000146828 Solute carrier family 12, member 9 7 100826820-100867009 Predicted membrane proteins, Transporters Evidence at protein level Ovarian cancer:4.00e-4 (unfavourable), Renal cancer:4.92e-4 (unfavourable), Lung cancer:5.97e-4 (favourable) Expressed in all Mixed placenta: 20.0 SLC13A3 NADC3, SDCT2 ENSG00000158296 Solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 20 46557823-46684467 Predicted membrane proteins, Transporters Evidence at protein level HPA014353, HPA014736 Supported Mixed Tissue enriched 7 kidney: 428.6 placenta: 60.6 SLC14A1 HsT1341, JK, RACH1, RACH2 ENSG00000141469 Solute carrier family 14 (urea transporter), member 1 (Kidd blood group) 18 45724127-45752520 Blood group antigen proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA058353, HPA059570 Supported Supported Vesicles Group enriched Group enriched 5 prostate: 132.1;urinary bladder: 51.9 cerebral cortex: 18.2 SLC15A3 hPTR3, PHT2 ENSG00000110446 Solute carrier family 15 (oligopeptide transporter), member 3 11 60937083-60952530 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA047880, HPA057642 Approved Supported Vesicles Cervical cancer:4.07e-5 (favourable) Expressed in all Expressed in all lung: 102.3 SLC16A11 FLJ90193, MCT11 ENSG00000174326 Solute carrier family 16, member 11 17 7041630-7043923 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at transcript level Renal cancer:3.19e-7 (favourable), Pancreatic cancer:1.45e-5 (favourable), Liver cancer:2.56e-4 (favourable) Tissue enhanced Tissue enhanced fallopian tube: 8.8;parathyroid gland: 11.2 seminal vesicle: 3.8 SLC16A6 MCT6, MCT7 ENSG00000108932 Solute carrier family 16, member 6 17 68267026-68291267 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA054459, HPA066328 Uncertain Approved Vesicles Group enriched Tissue enhanced epididymis: 39.8 esophagus: 12.1 SLC16A7 MCT2 ENSG00000118596 Solute carrier family 16 (monocarboxylate transporter), member 7 12 59596067-59789855 Predicted membrane proteins, Transporters Evidence at protein level HPA005911 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:8.85e-5 (favourable) Mixed Mixed adipose tissue: 24.8 SLC1A1 EAAC1, EAAT3 ENSG00000106688 Solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 9 4490444-4587469 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB015466, HPA020086 Approved Renal cancer:2.86e-8 (favourable) Expressed in all Tissue enhanced small intestine: 72.7 epididymis: 53.8 SLC1A2 EAAT2, GLT-1 ENSG00000110436 Solute carrier family 1 (glial high affinity glutamate transporter), member 2 11 35251206-35420063 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB002574, HPA009172 Supported Tissue enriched Tissue enriched 30 cerebral cortex: 367.1 liver: 12.2 SLC1A4 ASCT1, SATT ENSG00000115902 Solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 2 64988477-65023865 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA034963, HPA034964 Approved Validated Microtubule organizing center
Centrosome Liver cancer:4.23e-5 (unfavourable), Cervical cancer:3.59e-4 (favourable), Renal cancer:4.87e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 79.3 SLC1A6 EAAT4 ENSG00000105143 Solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6 19 14950034-15022990 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041505, HPA044066 Supported Uncertain Intermediate filaments Urothelial cancer:6.88e-6 (unfavourable) Tissue enriched Group enriched 6 cerebral cortex: 16.2;skin: 8.9;testis: 36.8 epididymis: 3.7 SLC1A7 EAAT5 ENSG00000162383 Solute carrier family 1 (glutamate transporter), member 7 1 53087179-53142632 Predicted membrane proteins, Transporters Evidence at protein level Tissue enhanced Tissue enhanced gallbladder: 8.5 fallopian tube: 4.4 SLC22A11 OAT4 ENSG00000168065 Solute carrier family 22 (organic anion/urate transporter), member 11 11 64555626-64572875 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA026076 Approved Renal cancer:3.68e-5 (favourable) Group enriched Group enriched 134 epididymis: 10.0;kidney: 25.9;placenta: 44.5 seminal vesicle: 0.2 SLC22A18 BWR1A, BWSCR1A, IMPT1, ITM, ORCTL2, SLC22A1L, TSSC5 ENSG00000110628 Solute carrier family 22, member 18 11 2899721-2925246 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA067812, HPA071461 Approved Expressed in all Tissue enhanced duodenum: 44.5;small intestine: 32.4 colon: 10.5 SLC22A7 NLT, OAT2 ENSG00000137204 Solute carrier family 22 (organic anion transporter), member 7 6 43295694-43305538 Predicted membrane proteins, Transporters Evidence at protein level HPA030220 Approved Liver cancer:5.48e-6 (favourable), Renal cancer:8.98e-4 (favourable) Tissue enriched Group enriched 63 kidney: 50.1;liver: 167.4 testis: 1.7 SLC23A3 FLJ31168, SVCT3, Yspl1 ENSG00000213901 Solute carrier family 23, member 3 2 219161465-219170095 Predicted membrane proteins, Transporters Evidence at protein level HPA019059 Approved Nucleus
Cell Junctions Tissue enriched Tissue enhanced kidney: 52.7;small intestine: 23.3 duodenum: 9.0 SLC25A10 DIC ENSG00000183048 Solute carrier family 25 (mitochondrial carrier; dicarboxylate transporter), member 10 17 81712236-81721016 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA023048 Supported Supported Nucleoplasm
Mitochondria Urothelial cancer:1.31e-4 (favourable), Head and neck cancer:2.56e-4 (favourable), Ovarian cancer:8.14e-4 (favourable) Expressed in all Mixed kidney: 35.3 SLC25A22 EIEE3, FLJ13044, GC1, NET44 ENSG00000177542 Solute carrier family 25 (mitochondrial carrier: glutamate), member 22 11 790475-798333 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA014662 Approved Validated Nucleoplasm
Mitochondria Expressed in all Tissue enriched 6 cerebral cortex: 89.9 testis: 15.2 SLC25A3 PHC ENSG00000075415 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3 12 98593591-98606379 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA045709 Supported Mitochondria Renal cancer:8.11e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 583.9 SLC25A39 CGI-69, FLJ22407 ENSG00000013306 Solute carrier family 25, member 39 17 44319625-44324870 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at transcript level HPA026785 Approved Renal cancer:3.58e-5 (favourable), Liver cancer:5.90e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 181.5 SLC25A4 ANT1, PEO2, PEO3, T1 ENSG00000151729 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 4 185143241-185150382 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046835, HPA071684 Approved Supported Mitochondria Renal cancer:0.00e+0 (favourable), Pancreatic cancer:3.41e-4 (favourable) Expressed in all Tissue enhanced heart muscle: 119.0;skeletal muscle: 66.2 cerebral cortex: 38.2 SLC25A40 MCFP ENSG00000075303 Solute carrier family 25, member 40 7 87833568-87876357 Predicted membrane proteins, Transporters Evidence at protein level HPA055197 Uncertain Renal cancer:1.52e-5 (favourable), Liver cancer:1.93e-4 (unfavourable) Expressed in all Mixed prostate: 13.6 SLC25A42 MGC26694 ENSG00000181035 Solute carrier family 25, member 42 19 19063999-19112888 Predicted membrane proteins, Transporters Evidence at protein level HPA049449 Approved Supported Mitochondria Lung cancer:4.11e-4 (favourable), Cervical cancer:5.04e-4 (favourable) Expressed in all Expressed in all kidney: 28.7 SLC25A45 ENSG00000162241 Solute carrier family 25, member 45 11 65375192-65383701 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA050821 Uncertain Approved Nucleoplasm
Cytosol Pancreatic cancer:2.83e-4 (favourable) Expressed in all Expressed in all spleen: 12.6 SLC25A48 FLJ44862, HDMCP ENSG00000145832 Solute carrier family 25, member 48 5 135834649-135888637 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA014674 Uncertain Approved Intermediate filaments
Actin filaments Mixed Tissue enhanced cerebral cortex: 17.7;kidney: 7.3 skeletal muscle: 2.7 SLC25A5 2F1, ANT2, T2, T3 ENSG00000005022 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5 X 119468400-119471319 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA046835, HPA071684 Approved Supported Mitochondria Renal cancer:8.06e-6 (favourable), Cervical cancer:7.35e-4 (favourable), Colorectal cancer:7.47e-4 (favourable) Expressed in all Expressed in all duodenum: 791.0 SLC26A1 EDM4, SAT-1 ENSG00000145217 Solute carrier family 26 (anion exchanger), member 1 4 979073-993440 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041654 Uncertain Approved Microtubules Renal cancer:1.19e-4 (favourable) Mixed Mixed kidney: 6.1 SLC26A6 DKFZp586E1422 ENSG00000225697 Solute carrier family 26 (anion exchanger), member 6 3 48625723-48635493 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA048363 Approved Uncertain Cytosol Renal cancer:1.53e-5 (unfavourable), Liver cancer:3.92e-4 (unfavourable) Expressed in all Expressed in all rectum: 24.3 SLC27A3 ACSVL3, FATP3, MGC4365 ENSG00000143554 Solute carrier family 27 (fatty acid transporter), member 3 1 153774354-153780157 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA006935, HPA067508 Uncertain Supported Endoplasmic reticulum Pancreatic cancer:5.23e-4 (favourable), Renal cancer:6.33e-4 (unfavourable) Expressed in all Tissue enhanced epididymis: 43.7 lung: 20.9 SLC27A5 ACSB, ACSVL6, FACVL3, FATP5, FLJ22987, VLACSR, VLCS-H2, VLCSH2 ENSG00000083807 Solute carrier family 27 (fatty acid transporter), member 5 19 58479512-58512413 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA007292, CAB056160, CAB068239 Supported Liver cancer:1.57e-4 (favourable) Tissue enriched Tissue enriched 23 liver: 335.8 fallopian tube: 14.4 SLC29A4 ENT4, FLJ34923 ENSG00000164638 Solute carrier family 29 (equilibrative nucleoside transporter), member 4 7 5274369-5306870 Predicted membrane proteins, Transporters Evidence at protein level HPA052829 Supported Microtubules
Cytokinetic bridge Pancreatic cancer:4.52e-4 (favourable) Expressed in all Tissue enhanced adipose tissue: 44.2 cerebral cortex: 12.0 SLC2A1 CSE, DYT18, DYT9, GLUT, GLUT1, HTLVR ENSG00000117394 Solute carrier family 2 (facilitated glucose transporter), member 1 1 42925375-42959173 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002759, HPA031345, HPA058494 Supported Supported Validated Plasma membrane Renal cancer:4.55e-9 (unfavourable), Liver cancer:3.65e-8 (unfavourable), Pancreatic cancer:4.39e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Urothelial cancer:4.05e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 133.9 skin: 31.3 SLC30A3 ZNT3 ENSG00000115194 Solute carrier family 30 (zinc transporter), member 3 2 27253684-27275817 Predicted membrane proteins, Transporters Evidence at protein level HPA060505, HPA067637 Approved Approved Nucleus
Nucleoli
Vesicles
Cytosol Mixed Group enriched 14 cerebral cortex: 36.7;epididymis: 65.2;testis: 43.6 heart muscle: 3.4 SLC34A1 NAPI-3, NPT2, NPTIIa, SLC11, SLC17A2 ENSG00000131183 Solute carrier family 34 (type II sodium/phosphate cotransporter), member 1 5 177379235-177398848 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA051255 Approved Tissue enriched Tissue enriched 164 kidney: 161.0 liver: 0.9 SLC35A1 CMPST, hCST ENSG00000164414 Solute carrier family 35 (CMP-sialic acid transporter), member A1 6 87470623-87512336 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:2.70e-6 (unfavourable) Expressed in all Expressed in all prostate: 59.9 SLC35A2 UGALT, UGAT, UGT, UGT1, UGT2, UGTL ENSG00000102100 Solute carrier family 35 (UDP-galactose transporter), member A2 X 48903180-48911958 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036087 Approved Supported Golgi apparatus Liver cancer:9.64e-5 (unfavourable), Breast cancer:3.16e-4 (unfavourable), Stomach cancer:8.23e-4 (favourable) Expressed in all Expressed in all fallopian tube: 44.1 SLC35A5 FLJ20730 ENSG00000138459 Solute carrier family 35, member A5 3 112561709-112585577 Predicted membrane proteins, Transporters Evidence at protein level HPA035519, HPA057964 Uncertain Approved Golgi apparatus Renal cancer:4.10e-5 (favourable) Expressed in all Expressed in all thyroid gland: 43.7 SLC35E2 KIAA0447 ENSG00000215790 Solute carrier family 35, member E2 1 1724838-1745992 Predicted membrane proteins Evidence at transcript level HPA062711 Uncertain Uncertain Nucleus Mixed Mixed thyroid gland: 7.5 SLC35E4 ENSG00000100036 Solute carrier family 35, member E4 22 30635652-30669016 Predicted membrane proteins, Transporters Evidence at transcript level HPA049558 Approved Approved Cytosol Mixed Tissue enhanced testis: 17.6 cerebral cortex: 5.1 SLC36A1 LYAAT-1, PAT1, TRAMD3 ENSG00000123643 Solute carrier family 36 (proton/amino acid symporter), member 1 5 151437046-151492381 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA035937 Approved Renal cancer:1.83e-6 (unfavourable), Liver cancer:6.30e-5 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 64.1 duodenum: 45.5 SLC37A2 FLJ00171 ENSG00000134955 Solute carrier family 37 (glucose-6-phosphate transporter), member 2 11 125063067-125090312 Predicted membrane proteins, Transporters Evidence at protein level HPA014948 Uncertain Expressed in all Mixed adrenal gland: 24.8 SLC37A3 DKFZp761N0624 ENSG00000157800 Solute carrier family 37, member 3 7 140293693-140404433 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA014713, HPA061841 Supported Cytosol Liver cancer:4.78e-5 (unfavourable), Cervical cancer:9.54e-4 (unfavourable) Expressed in all Expressed in all endometrium: 72.5 SLC38A10 MGC15523, PP1744 ENSG00000157637 Solute carrier family 38, member 10 17 81245000-81295547 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA021374, HPA023161, HPA024631 Supported Validated Golgi apparatus Renal cancer:5.34e-7 (unfavourable), Pancreatic cancer:2.92e-4 (favourable) Expressed in all Expressed in all thyroid gland: 44.6 SLC38A11 AVT2, FLJ39822 ENSG00000169507 Solute carrier family 38, member 11 2 164896186-164955525 Predicted membrane proteins, Transporters Evidence at transcript level HPA043432 Uncertain Renal cancer:2.00e-8 (favourable) Tissue enriched Tissue enhanced epididymis: 47.1;gallbladder: 28.3 seminal vesicle: 23.3 SLC38A4 ATA3, NAT3, PAAT ENSG00000139209 Solute carrier family 38, member 4 12 46764761-46832408 Predicted membrane proteins, Transporters Evidence at protein level Liver cancer:5.37e-4 (favourable) Tissue enriched Tissue enriched 40 liver: 346.5 smooth muscle: 8.6 SLC38A5 JM24, SN2 ENSG00000017483 Solute carrier family 38, member 5 X 48458537-48470256 Predicted membrane proteins, Transporters Evidence at protein level HPA047411 Approved Approved Vesicles
Plasma membrane
Cytosol Renal cancer:2.22e-16 (unfavourable), Pancreatic cancer:2.13e-4 (unfavourable) Expressed in all Mixed pancreas: 50.0 SLC38A6 NAT-1 ENSG00000139974 Solute carrier family 38, member 6 14 60981114-61083733 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018508 Approved Approved Plasma membrane
Cell Junctions
Microtubules Liver cancer:9.47e-6 (unfavourable), Renal cancer:1.37e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 24.3 SLC38A7 FLJ10815 ENSG00000103042 Solute carrier family 38, member 7 16 58665109-58685104 Predicted membrane proteins, Transporters Evidence at protein level HPA041777 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:2.87e-4 (favourable), Endometrial cancer:6.87e-4 (favourable) Expressed in all Mixed testis: 34.8 SLC38A9 FLJ90709 ENSG00000177058 Solute carrier family 38, member 9 5 55625845-55773194 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA043785 Uncertain Approved Nucleoplasm
Vesicles Endometrial cancer:7.24e-5 (unfavourable) Expressed in all Expressed in all placenta: 79.8 SLC39A1 ZIP1, ZIRTL ENSG00000143570 Solute carrier family 39 (zinc transporter), member 1 1 153959099-153968184 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA016506 Uncertain Cytosol Liver cancer:4.12e-7 (unfavourable), Head and neck cancer:5.26e-5 (unfavourable), Cervical cancer:4.83e-4 (unfavourable) Expressed in all Expressed in all placenta: 133.4 SLC39A11 C17orf26 ENSG00000133195 Solute carrier family 39, member 11 17 72645949-73092712 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA021455 Approved Nucleoplasm Expressed in all Expressed in all thyroid gland: 60.0 SLC39A13 FLJ25785 ENSG00000165915 Solute carrier family 39 (zinc transporter), member 13 11 47407132-47416501 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA043971 Approved Uncertain Cytosol Ovarian cancer:2.73e-5 (unfavourable), Renal cancer:1.96e-4 (favourable), Colorectal cancer:2.60e-4 (unfavourable) Expressed in all Expressed in all placenta: 58.0 SLC39A7 D6S2244E, H2-KE4, HKE4, KE4, RING5, ZIP7 ENSG00000112473 Solute carrier family 39 (zinc transporter), member 7 6 33200445-33204439 Predicted membrane proteins, Transporters Evidence at protein level HPA053999 Approved Supported Endoplasmic reticulum Liver cancer:3.62e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 40.2 SLC40A1 FPN1, HFE4, IREG1, MTP1, SLC11A3 ENSG00000138449 Solute carrier family 40 (iron-regulated transporter), member 1 2 189560579-189583758 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA065634 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:8.55e-5 (favourable) Expressed in all Expressed in all spleen: 496.0 SLC41A2 DKFZP434K0427 ENSG00000136052 Solute carrier family 41 (magnesium transporter), member 2 12 104802553-104958744 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA038658 Approved Renal cancer:3.35e-4 (unfavourable), Liver cancer:9.94e-4 (favourable) Expressed in all Mixed liver: 59.8 SLC41A3 FLJ20473 ENSG00000114544 Solute carrier family 41, member 3 3 126006355-126101561 Predicted membrane proteins, Transporters Evidence at protein level HPA045847 Approved Supported Plasma membrane Liver cancer:1.49e-7 (unfavourable), Renal cancer:6.04e-7 (favourable) Expressed in all Expressed in all testis: 79.0 SLC43A1 PB39, POV1, R00504 ENSG00000149150 Solute carrier family 43 (amino acid system L transporter), member 1 11 57484534-57515786 Predicted membrane proteins, Transporters Evidence at protein level HPA018813, HPA018826 Supported Approved Golgi apparatus
Vesicles
Plasma membrane Renal cancer:2.97e-5 (unfavourable), Endometrial cancer:3.19e-4 (favourable), Thyroid cancer:5.27e-4 (unfavourable) Expressed in all Expressed in all liver: 50.0 SLC43A3 DKFZp762A227, Eeg1, FOAP-13, PRO1659, SEEEG-1 ENSG00000134802 Solute carrier family 43, member 3 11 57406954-57427580 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA030551 Approved Renal cancer:3.97e-13 (unfavourable) Expressed in all Expressed in all thyroid gland: 121.6 SLC45A4 KIAA1126 ENSG00000022567 Solute carrier family 45, member 4 8 141207166-141308305 Predicted membrane proteins, Transporters Evidence at protein level HPA023154 Uncertain Approved Plasma membrane Renal cancer:1.73e-6 (favourable) Expressed in all Mixed testis: 21.1 SLC46A1 HCP1, MGC9564, PCFT ENSG00000076351 Solute carrier family 46 (folate transporter), member 1 17 28394756-28407197 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB011614 Approved Supported Plasma membrane
Cytosol Glioma:3.90e-4 (unfavourable) Expressed in all Expressed in all duodenum: 97.7 SLC5A6 SMVT ENSG00000138074 Solute carrier family 5 (sodium/multivitamin and iodide cotransporter), member 6 2 27199587-27212958 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA036958 Approved Approved Cell Junctions Renal cancer:3.60e-7 (unfavourable) Expressed in all Expressed in all epididymis: 82.1 SLC6A11 GAT3 ENSG00000132164 Solute carrier family 6 (neurotransmitter transporter), member 11 3 10816200-10940733 Predicted membrane proteins, Transporters Evidence at protein level HPA037981 Supported Supported Tissue enhanced Tissue enhanced cerebral cortex: 18.2;skin: 6.7 esophagus: 5.5 SLC6A12 BGT-1 ENSG00000111181 Solute carrier family 6 (neurotransmitter transporter), member 12 12 190077-214570 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA034973, HPA057917 Approved Approved Golgi apparatus Renal cancer:2.70e-6 (favourable), Endometrial cancer:1.59e-4 (unfavourable) Tissue enhanced Tissue enhanced kidney: 29.4;liver: 43.6 cerebral cortex: 14.8 SLC6A16 NTT5 ENSG00000063127 Solute carrier family 6, member 16 19 49289638-49325225 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at transcript level HPA076812 Approved Golgi apparatus Mixed Tissue enriched 18 testis: 161.8 lymph node: 9.0 SLC6A2 NAT1, NET, NET1, SLC6A5 ENSG00000103546 Solute carrier family 6 (neurotransmitter transporter), member 2 16 55655604-55706192 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA004057, CAB078195 Supported Supported Approved Mitochondria
Cytosol Tissue enhanced Tissue enhanced adrenal gland: 29.4;placenta: 18.2;skin: 15.7 testis: 11.4 SLC6A6 TAUT ENSG00000131389 Solute carrier family 6 (neurotransmitter transporter), member 6 3 14402576-14489349 Predicted membrane proteins, Transporters Evidence at protein level HPA015028, HPA016488 Supported Approved Cell Junctions
Cytosol Glioma:1.09e-7 (unfavourable), Endometrial cancer:5.22e-5 (favourable), Liver cancer:8.78e-4 (unfavourable) Expressed in all Mixed ovary: 50.7 SLC7A1 ATRC1, CAT-1, ERR, HCAT1, REC1L ENSG00000139514 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 13 29509410-29595688 Predicted membrane proteins, Transporters Evidence at protein level HPA039721 Approved Renal cancer:1.32e-5 (unfavourable) Expressed in all Mixed esophagus: 42.0 SLC7A7 LPI, y+LAT-1 ENSG00000155465 Solute carrier family 7 (amino acid transporter light chain, y+L system), member 7 14 22773222-22829820 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036227 Approved Renal cancer:6.28e-6 (unfavourable) Expressed in all Tissue enhanced kidney: 279.7 parathyroid gland: 159.0 SLC7A8 LAT2, LPI-PC1 ENSG00000092068 Solute carrier family 7 (amino acid transporter light chain, L system), member 8 14 23125295-23183674 Predicted membrane proteins, Transporters Evidence at protein level CAB046015, HPA051950, HPA060672 Supported Urothelial cancer:1.52e-4 (unfavourable), Liver cancer:1.97e-4 (unfavourable), Lung cancer:3.15e-4 (favourable) Expressed in all Tissue enriched 8 parathyroid gland: 1066.4 kidney: 131.5 SLC8A2 KIAA1087, NCX2 ENSG00000118160 Solute carrier family 8 (sodium/calcium exchanger), member 2 19 47428017-47472168 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA050818, HPA054671 Supported Mixed Tissue enriched 11 cerebral cortex: 68.4 endometrium: 6.2 SLC8B1 FLJ22233, NCKX6, NCLX, SLC24A6 ENSG00000089060 Solute carrier family 8 (sodium/lithium/calcium exchanger), member B1 12 113298759-113359493 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA040668 Approved Urothelial cancer:5.02e-4 (favourable), Breast cancer:9.52e-4 (favourable) Expressed in all Expressed in all adrenal gland: 48.6 SLC9A5 NHE5 ENSG00000135740 Solute carrier family 9, subfamily A (NHE5, cation proton antiporter 5), member 5 16 67237683-67272190 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041004, HPA041329 Uncertain Approved Nucleoplasm
Cytosol Mixed Tissue enhanced spleen: 7.8 cerebral cortex: 2.5 SLC9B1 NHA1, NHEDC1 ENSG00000164037 Solute carrier family 9, subfamily B (NHA1, cation proton antiporter 1), member 1 4 102885048-103019739 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA035435, HPA058971, HPA065520 Uncertain Approved Mitochondria Mixed Tissue enriched 25 testis: 73.9 epididymis: 2.9 SOAT1 ACAT, SOAT, STAT ENSG00000057252 Sterol O-acyltransferase 1 1 179293714-179358680 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB009533, HPA047171 Supported Validated Endoplasmic reticulum Expressed in all Tissue enhanced adrenal gland: 219.3 prostate: 44.0 SPAG4 CT127, SUN4 ENSG00000061656 Sperm associated antigen 4 20 35615892-35621049 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048393, HPA061789 Approved Endometrial cancer:9.52e-8 (favourable), Colorectal cancer:1.09e-5 (unfavourable), Glioma:8.89e-5 (unfavourable), Renal cancer:1.28e-4 (unfavourable), Urothelial cancer:6.66e-4 (favourable) Expressed in all Mixed testis: 22.6 SPNS1 HSpin1, LAT, nrs, PP2030, SPIN1, SPINL ENSG00000169682 Spinster homolog 1 (Drosophila) 16 28974221-28984548 Predicted membrane proteins, Transporters Evidence at protein level HPA041995, HPA042988 Supported Approved Nucleoli fibrillar center
Golgi apparatus
Vesicles
Cytosol Mixed Expressed in all parathyroid gland: 36.3 SPNS2 ENSG00000183018 Spinster homolog 2 (Drosophila) 17 4498838-4539035 Predicted membrane proteins, Transporters Evidence at protein level HPA068717 Uncertain Expressed in all Tissue enhanced esophagus: 46.5 kidney: 29.9 SQLE ENSG00000104549 Squalene epoxidase 8 124998497-125022283 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018038, HPA020762 Approved Uncertain Vesicles
Cytosol Pancreatic cancer:2.73e-4 (unfavourable), Lung cancer:4.67e-4 (unfavourable), Renal cancer:5.70e-4 (unfavourable), Head and neck cancer:7.42e-4 (unfavourable) Expressed in all Mixed testis: 107.2 SSR3 TRAPG ENSG00000114850 Signal sequence receptor, gamma (translocon-associated protein gamma) 3 156540140-156555184 Predicted membrane proteins Evidence at protein level HPA014906 Approved Approved Uncertain Cytosol Liver cancer:4.46e-7 (unfavourable), Renal cancer:2.84e-4 (unfavourable), Head and neck cancer:3.43e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 203.5 ST7 ETS7q, FAM4A, FAM4A1, HELG, RAY1, SEN4, TSG7 ENSG00000004866 Suppression of tumorigenicity 7 7 116953238-117230103 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038325, HPA038326 Approved Supported Nucleoplasm
Cytosol Renal cancer:3.39e-5 (favourable) Expressed in all Expressed in all thyroid gland: 50.9 ST7L FAM4B, FLJ20284, ST7R, STLR ENSG00000007341 Suppression of tumorigenicity 7 like 1 112523518-112620825 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA042324, HPA075418 Uncertain Approved Centrosome Ovarian cancer:3.04e-5 (favourable), Colorectal cancer:8.34e-5 (favourable), Melanoma:5.16e-4 (unfavourable), Endometrial cancer:8.96e-4 (unfavourable) Expressed in all Tissue enriched 5 testis: 64.6 thyroid gland: 12.3 STARD3 es64, MLN64 ENSG00000131748 StAR-related lipid transfer (START) domain containing 3 17 39637065-39663484 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level CAB017021 Uncertain Liver cancer:3.60e-5 (unfavourable), Renal cancer:7.70e-4 (unfavourable) Expressed in all Expressed in all testis: 33.3 STEAP1B ENSG00000105889 STEAP family member 1B 7 22419444-22632925 Predicted membrane proteins Evidence at transcript level Tissue enhanced Tissue enhanced testis: 5.3 spleen: 3.5 STEAP4 FLJ23153, STAMP2, TIARP, TNFAIP9 ENSG00000127954 STEAP family member 4 7 88270892-88306891 Predicted membrane proteins, Transporters Evidence at protein level HPA075871 Supported Golgi apparatus Liver cancer:2.97e-4 (favourable), Stomach cancer:5.77e-4 (unfavourable) Tissue enhanced Expressed in all adipose tissue: 129.9 SUCO C1orf9, CH1, OPT, SLP1 ENSG00000094975 SUN domain containing ossification factor 1 172532349-172611833 Predicted membrane proteins Evidence at protein level HPA047251 Approved Approved Nucleoli fibrillar center
Cytosol Liver cancer:2.86e-4 (unfavourable) Expressed in all Mixed epididymis: 75.0 SUN1 FLJ12407, KIAA0810, UNC84A ENSG00000164828 Sad1 and UNC84 domain containing 1 7 816615-896435 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008346, HPA008461 Supported Validated Nuclear membrane Expressed in all Expressed in all endometrium: 120.0 SYNGR1 ENSG00000100321 Synaptogyrin 1 22 39349925-39385588 Predicted membrane proteins Evidence at protein level HPA029673, CAB034277 Supported Supported Cytosol Renal cancer:4.98e-7 (favourable), Pancreatic cancer:2.41e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 175.9 SYNGR2 ENSG00000108639 Synaptogyrin 2 17 78168558-78173527 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014742 Approved Approved Golgi apparatus Renal cancer:5.37e-4 (unfavourable) Expressed in all Expressed in all lung: 155.0 SYNGR4 ENSG00000105467 Synaptogyrin 4 19 48364395-48376376 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA030075, HPA059286 Approved Approved Golgi apparatus Mixed Tissue enriched 11 testis: 46.8 parathyroid gland: 4.4 SYNPR MGC26651, SPO ENSG00000163630 Synaptoporin 3 63228315-63616921 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051368, HPA061671 Supported Tissue enhanced Tissue enriched 23 cerebral cortex: 78.4 heart muscle: 3.3 SYPL1 SYPL ENSG00000008282 Synaptophysin-like 1 7 106090503-106112576 Predicted membrane proteins Evidence at protein level HPA014141 Approved Renal cancer:1.25e-9 (favourable) Expressed in all Expressed in all thyroid gland: 194.0 SYS1 C20orf169, dJ453C12.4 ENSG00000204070 Sys1 golgi trafficking protein 20 45361937-45376798 Predicted membrane proteins Evidence at protein level HPA046716 Approved Liver cancer:4.62e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 51.3 TBC1D19 FLJ11082 ENSG00000109680 TBC1 domain family, member 19 4 26576437-26755351 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039592 Approved Approved Nucleoplasm
Nuclear membrane Renal cancer:1.21e-7 (favourable), Thyroid cancer:4.06e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 22.7 TBC1D20 C20orf140, dJ852M4.2 ENSG00000125875 TBC1 domain family, member 20 20 435480-462553 Disease related genes, Predicted membrane proteins Evidence at protein level HPA043613 Approved Expressed in all Expressed in all parathyroid gland: 30.7 TBC1D8 AD3, HBLP1, VRP ENSG00000204634 TBC1 domain family, member 8 (with GRAM domain) 2 101007617-101252866 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB015211, HPA037496 Uncertain Supported Nucleus Colorectal cancer:6.73e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 44.7 TBXA2R ENSG00000006638 Thromboxane A2 receptor 19 3594506-3606840 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA077366 Supported Nuclear speckles
Plasma membrane Renal cancer:1.45e-4 (unfavourable), Pancreatic cancer:7.17e-4 (favourable) Expressed in all Mixed spleen: 5.3 TECR GPSN2, MRT14, SC2, TER ENSG00000099797 Trans-2,3-enoyl-CoA reductase 19 14517085-14565980 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029780, HPA056488 Supported Supported Endoplasmic reticulum Urothelial cancer:2.60e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 397.0 TEX28 CXorf2, fTEX ENSG00000278057 Testis expressed 28 X 154271265-154295853 Predicted membrane proteins Evidence at transcript level Not detected Tissue enriched 33 testis: 6.2 bone marrow,skin: 0.1 TGIF2-C20orf24 ENSG00000259399 TGIF2-C20orf24 readthrough 20 36574553-36612384 Predicted membrane proteins Evidence at transcript level Not detected Mixed appendix: 11.9 TIMM17B DXS9822, JM3 ENSG00000126768 Translocase of inner mitochondrial membrane 17 homolog B (yeast) X 48893447-48898143 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029093 Approved Approved Microtubules
Mitochondria Cervical cancer:6.63e-4 (favourable), Urothelial cancer:7.88e-4 (favourable) Expressed in all Expressed in all fallopian tube: 43.4 TM4SF18 L6D ENSG00000163762 Transmembrane 4 L six family member 18 3 149318498-149334414 Predicted membrane proteins Evidence at transcript level HPA053639, HPA069378 Approved Uncertain Nucleoli
Vesicles Liver cancer:8.63e-4 (favourable) Expressed in all Mixed spleen: 47.6 TM4SF19 ENSG00000145107 Transmembrane 4 L six family member 19 3 196319342-196338503 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level Tissue enhanced Tissue enhanced testis: 11.3 esophagus,lung: 3.1 TM4SF20 FLJ22800, TCCE518 ENSG00000168955 Transmembrane 4 L six family member 20 2 227362156-227381995 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051838, HPA063184, HPA065531 Uncertain Supported Plasma membrane
Focal adhesion sites Group enriched Group enriched 36 duodenum: 285.0;small intestine: 167.3 testis: 6.3 TM4SF5 ENSG00000142484 Transmembrane 4 L six family member 5 17 4771884-4783213 Predicted membrane proteins Evidence at protein level HPA055674 Uncertain Nucleoplasm
Plasma membrane
Cell Junctions Tissue enriched Group enriched 5 duodenum: 181.8;small intestine: 172.8 liver: 33.2 TMBIM6 BAXI1, BI-1, TEGT ENSG00000139644 Transmembrane BAX inhibitor motif containing 6 12 49707725-49764934 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA017378 Approved Renal cancer:1.00e-5 (favourable), Head and neck cancer:1.91e-4 (unfavourable), Breast cancer:3.54e-4 (unfavourable) Expressed in all Expressed in all kidney: 1179.3 TMCO1 HP10122, TMCC4 ENSG00000143183 Transmembrane and coiled-coil domains 1 1 165724293-165827755 Disease related genes, Predicted membrane proteins Evidence at protein level HPA054768 Supported Endoplasmic reticulum Head and neck cancer:5.17e-7 (unfavourable), Renal cancer:1.25e-4 (unfavourable), Liver cancer:3.21e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 157.3 TMEM107 MGC10744 ENSG00000179029 Transmembrane protein 107 17 8173237-8176399 Predicted membrane proteins Evidence at transcript level HPA052555, HPA059653 Approved Approved Nucleoplasm
Midbody
Midbody ring
Cytosol Endometrial cancer:9.39e-5 (favourable) Expressed in all Mixed fallopian tube: 71.3 TMEM114 ENSG00000232258 Transmembrane protein 114 16 8537605-8590193 Disease related genes, Predicted membrane proteins Evidence at transcript level Not detected Tissue enriched 62 seminal vesicle: 28.3 epididymis: 0.4 TMEM116 FLJ90167 ENSG00000198270 Transmembrane protein 116 12 111931282-112013185 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA040720 Approved Approved Nucleoplasm
Microtubules Renal cancer:1.08e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 56.1 testis: 47.8 TMEM120A NET29, TMPIT ENSG00000189077 Transmembrane protein 120A 7 75986837-75994659 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Expressed in all Expressed in all small intestine: 73.9 TMEM120B ENSG00000188735 Transmembrane protein 120B 12 121712752-121783001 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014066 Uncertain Liver cancer:1.66e-5 (unfavourable) Expressed in all Mixed endometrium: 12.1 TMEM125 MGC17299 ENSG00000179178 Transmembrane protein 125 1 43269994-43274002 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA015796 Approved Midbody
Cytosol Renal cancer:2.91e-9 (favourable), Lung cancer:5.11e-5 (favourable) Mixed Tissue enhanced lung: 113.9 thyroid gland: 51.5 TMEM126B HT007 ENSG00000171204 Transmembrane protein 126B 11 85628573-85636539 Predicted membrane proteins Evidence at protein level HPA014480, HPA019186 Uncertain Supported Mitochondria Expressed in all Expressed in all epididymis: 39.2 TMEM127 FLJ20507, FLJ22257 ENSG00000135956 Transmembrane protein 127 2 96248516-96265994 Disease related genes, Predicted membrane proteins Evidence at protein level Renal cancer:6.69e-5 (favourable), Liver cancer:6.59e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 110.4 TMEM128 MGC13159 ENSG00000132406 Transmembrane protein 128 4 4235542-4248212 Predicted membrane proteins Evidence at protein level HPA044809 Uncertain Expressed in all Expressed in all thyroid gland: 63.7 TMEM136 MGC17839 ENSG00000181264 Transmembrane protein 136 11 120325129-120333682 Predicted membrane proteins Evidence at transcript level HPA074432 Approved Vesicles
Cytosol Endometrial cancer:6.65e-4 (unfavourable) Expressed in all Mixed adrenal gland: 12.7 TMEM138 HSPC196, JBTS16 ENSG00000149483 Transmembrane protein 138 11 61362001-61369509 Disease related genes, Predicted membrane proteins Evidence at protein level HPA042373 Approved Approved Microtubules Renal cancer:4.12e-6 (unfavourable), Liver cancer:7.90e-4 (unfavourable) Expressed in all Expressed in all epididymis: 24.8 TMEM144 FLJ11155 ENSG00000164124 Transmembrane protein 144 4 158201604-158255411 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA043767, HPA063554 Uncertain Approved Mitochondria Endometrial cancer:2.89e-4 (favourable), Pancreatic cancer:8.48e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 90.8 testis: 46.6 TMEM14A C6orf73, PTD011 ENSG00000096092 Transmembrane protein 14A 6 52671109-52686588 Predicted membrane proteins Evidence at protein level HPA072536 Approved Nucleoplasm
Endoplasmic reticulum Expressed in all Expressed in all cerebral cortex: 88.4 TMEM14B MGC1223 ENSG00000137210 Transmembrane protein 14B 6 10747759-10852753 Predicted membrane proteins Evidence at protein level Liver cancer:9.35e-5 (unfavourable), Endometrial cancer:6.51e-4 (unfavourable), Ovarian cancer:7.41e-4 (favourable) Expressed in all Expressed in all thyroid gland: 204.2 TMEM150C FLJ12993 ENSG00000249242 Transmembrane protein 150C 4 82483170-82562357 Predicted membrane proteins Evidence at protein level HPA052921 Supported Renal cancer:4.59e-6 (favourable), Pancreatic cancer:5.68e-4 (favourable), Head and neck cancer:7.87e-4 (favourable) Expressed in all Tissue enhanced epididymis: 179.7 ovary: 43.5 TMEM151A MGC33486, TMEM151 ENSG00000179292 Transmembrane protein 151A 11 66291870-66296664 Predicted membrane proteins Evidence at transcript level HPA041035 Uncertain Approved Nucleoli
Cytosol Tissue enhanced Tissue enriched 24 cerebral cortex: 45.4 adrenal gland: 1.8 TMEM151B bA444E17.5, C6orf137, TMEM193 ENSG00000178233 Transmembrane protein 151B 6 44270466-44307506 Predicted membrane proteins Evidence at transcript level HPA055167 Uncertain Tissue enhanced Tissue enriched 10 cerebral cortex: 40.1 adrenal gland: 4.0 TMEM164 FLJ22679, RP13-360B22.2 ENSG00000157600 Transmembrane protein 164 X 110002631-110182734 Predicted membrane proteins Evidence at protein level HPA038784 Approved Approved Vesicles
Cell Junctions Liver cancer:8.17e-6 (unfavourable), Stomach cancer:3.14e-4 (favourable) Expressed in all Expressed in all lung: 26.7 TMEM170A FLJ37611, TMEM170 ENSG00000166822 Transmembrane protein 170A 16 75443054-75465497 Predicted membrane proteins Evidence at transcript level HPA055071 Uncertain Renal cancer:2.36e-9 (favourable) Expressed in all Expressed in all testis: 32.6 TMEM170B ENSG00000205269 Transmembrane protein 170B 6 11538278-11583524 Predicted membrane proteins Evidence at transcript level HPA055134 Uncertain Approved Centrosome Mixed Tissue enhanced cerebral cortex: 21.4 bone marrow: 16.9 TMEM171 PRP2 ENSG00000157111 Transmembrane protein 171 5 73120292-73131817 Predicted membrane proteins Evidence at protein level HPA042308 Approved Renal cancer:3.93e-10 (favourable) Mixed Tissue enhanced colon: 32.9;rectum: 32.7;thyroid gland: 47.0 duodenum: 27.1 TMEM173 FLJ38577, NET23 ENSG00000184584 Transmembrane protein 173 5 139475534-139482935 Disease related genes, Predicted membrane proteins Evidence at protein level HPA038116, HPA038534 Supported Supported Cytosol Renal cancer:3.59e-8 (unfavourable) Expressed in all Expressed in all lung: 70.2 TMEM175 MGC4618 ENSG00000127419 Transmembrane protein 175 4 932387-958656 Predicted membrane proteins, Transporters Evidence at protein level HPA057160 Approved Approved Nucleus
Nuclear membrane Pancreatic cancer:9.85e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 20.8 TMEM176A HCA112, MS4B1 ENSG00000002933 Transmembrane protein 176A 7 150800403-150805120 Predicted membrane proteins Evidence at protein level HPA008770 Approved Approved Mitochondria Expressed in all Expressed in all liver: 579.4 TMEM176B LR8, MS4B2 ENSG00000106565 Transmembrane protein 176B 7 150791285-150801360 Predicted membrane proteins Evidence at protein level HPA047509 Uncertain Approved Nucleoplasm
Golgi apparatus
Plasma membrane Expressed in all Expressed in all liver: 842.9 TMEM178A MGC33926, TMEM178 ENSG00000152154 Transmembrane protein 178A 2 39664982-39717963 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at transcript level HPA052128, HPA058560 Uncertain Approved Nucleus
Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 55.6 kidney: 19.1 TMEM178B DKFZp547G036 ENSG00000261115 Transmembrane protein 178B 7 141074232-141480380 Predicted membrane proteins Evidence at protein level HPA048771 Uncertain Uncertain Nucleoli
Vesicles Renal cancer:4.10e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 19.4;parathyroid gland: 28.5;thyroid gland: 14.3 heart muscle: 7.4 TMEM179 C14orf90, FLJ42486, TMEM179A ENSG00000258986 Transmembrane protein 179 14 104474678-104605647 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA002942 Uncertain Mitochondria Mixed Group enriched 8 adrenal gland: 14.7;cerebral cortex: 28.0 testis: 2.5 TMEM179B ENSG00000185475 Transmembrane protein 179B 11 62787415-62790405 Predicted membrane proteins Evidence at protein level HPA016585, HPA062068 Validated Nuclear speckles Expressed in all Expressed in all epididymis: 86.2 TMEM18 DKFZp434C1714 ENSG00000151353 Transmembrane protein 18 2 667335-677439 Predicted membrane proteins Evidence at protein level HPA040233 Approved Approved Mitochondria Melanoma:3.21e-4 (unfavourable) Expressed in all Expressed in all ovary: 43.9 TMEM182 FLJ30294 ENSG00000170417 Transmembrane protein 182 2 102736908-102843893 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045861 Uncertain Approved Nucleoplasm
Vesicles Expressed in all Group enriched 10 heart muscle: 60.3;skeletal muscle: 44.1 prostate: 5.0 TMEM184A MGC9712 ENSG00000164855 Transmembrane protein 184A 7 1542235-1560821 Predicted membrane proteins Evidence at protein level HPA053790, HPA071312 Uncertain Approved Nucleoplasm Colorectal cancer:1.12e-4 (unfavourable), Thyroid cancer:9.94e-4 (unfavourable) Mixed Tissue enhanced skin: 33.5 esophagus: 26.7 TMEM185A CXorf13, FAM11A, FRAXF ENSG00000269556 Transmembrane protein 185A X 149596556-149631912 Predicted membrane proteins Evidence at protein level HPA048295, HPA071744 Uncertain Approved Endoplasmic reticulum Expressed in all Expressed in all ovary: 36.3 TMEM189 Kua ENSG00000240849 Transmembrane protein 189 20 50118254-50153734 Predicted membrane proteins Evidence at protein level HPA059549 Approved Supported Endoplasmic reticulum Renal cancer:5.79e-11 (unfavourable), Endometrial cancer:7.51e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 31.1 TMEM189-UBE2V1 CROC-1B, Kua-UEV ENSG00000124208 TMEM189-UBE2V1 readthrough 20 50081124-50153637 Predicted membrane proteins Evidence at protein level HPA052535, HPA053186 Supported Nucleoplasm Not detected Mixed placenta: 5.5 TMEM19 FLJ10936 ENSG00000139291 Transmembrane protein 19 12 71686087-71705046 Predicted membrane proteins Evidence at protein level HPA016830 Approved Expressed in all Expressed in all kidney: 40.5 TMEM196 MGC42090 ENSG00000173452 Transmembrane protein 196 7 19719310-19773598 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA043163 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 9.2 endometrium: 2.1 TMEM204 C16orf30, CLP24, FLJ20898 ENSG00000131634 Transmembrane protein 204 16 1528688-1555580 Predicted membrane proteins Evidence at transcript level HPA014028 Approved Liver cancer:4.76e-4 (favourable), Melanoma:7.89e-4 (unfavourable) Expressed in all Mixed adipose tissue: 40.6 TMEM205 MBC3205, UNQ501 ENSG00000105518 Transmembrane protein 205 19 11342776-11346518 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA041504 Approved Approved Nucleoplasm
Nuclear membrane
Endoplasmic reticulum Expressed in all Expressed in all parathyroid gland: 253.1 TMEM211 bA9F11.1 ENSG00000206069 Transmembrane protein 211 22 24935110-24946695 Predicted membrane proteins Evidence at transcript level HPA066784 Uncertain Tissue enhanced Tissue enhanced cervix, uterine: 4.5;stomach: 3.4 salivary gland: 1.9 TMEM212 FLJ23172 ENSG00000186329 Transmembrane protein 212 3 171843349-171938715 Predicted membrane proteins Evidence at transcript level HPA045736, HPA053134 Uncertain Approved Nucleoli fibrillar center
Endoplasmic reticulum Not detected Tissue enriched 6 fallopian tube: 47.9 lung: 7.7 TMEM220 ENSG00000187824 Transmembrane protein 220 17 10699015-10730316 Predicted membrane proteins Evidence at protein level Liver cancer:2.23e-5 (favourable), Pancreatic cancer:1.72e-4 (favourable), Glioma:9.39e-4 (unfavourable) Expressed in all Expressed in all liver: 53.9 TMEM221 ENSG00000188051 Transmembrane protein 221 19 17435509-17448567 Predicted membrane proteins Evidence at protein level HPA041580 Approved Uncertain Nuclear membrane Tissue enhanced Tissue enhanced parathyroid gland: 7.0 fallopian tube: 4.4 TMEM222 C1orf160, DKFZP564D0478 ENSG00000186501 Transmembrane protein 222 1 27322145-27336400 Predicted membrane proteins Evidence at protein level HPA016579, HPA059374 Approved Approved Plasma membrane
Cytosol Expressed in all Expressed in all fallopian tube: 47.4 TMEM225 PMP22CD, PPP1R154 ENSG00000204300 Transmembrane protein 225 11 123882926-123885642 Predicted membrane proteins Evidence at transcript level Not detected Tissue enriched 395 testis: 39.4 all non-specific tissues: 0.0 TMEM234 C1orf91, dJ622L5.7, FLJ90779, RP4-622L5 ENSG00000160055 Transmembrane protein 234 1 32214472-32222359 Predicted membrane proteins, Transporters Evidence at protein level HPA015049 Uncertain Approved Vesicles Liver cancer:2.35e-5 (unfavourable), Renal cancer:4.12e-5 (unfavourable) Expressed in all Mixed epididymis: 12.8 TMEM235 ENSG00000204278 Transmembrane protein 235 17 78231310-78240987 Predicted membrane proteins Evidence at transcript level HPA053939 Uncertain Tissue enriched Tissue enriched 101 cerebral cortex: 15.7 placenta,testis: 0.1 TMEM242 BM033, C6orf35 ENSG00000215712 Transmembrane protein 242 6 157289386-157323601 Predicted membrane proteins Evidence at protein level HPA025764 Approved Expressed in all Expressed in all cerebral cortex: 17.0 TMEM243 C7orf23, MGC4175, MM-TRAG ENSG00000135185 Transmembrane protein 243, mitochondrial 7 87196160-87220587 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014918 Uncertain Lung cancer:5.45e-4 (favourable), Melanoma:6.84e-4 (unfavourable), Urothelial cancer:9.13e-4 (favourable) Expressed in all Expressed in all thyroid gland: 103.3 TMEM253 C14orf176, C14orf95, NCRNA00220 ENSG00000232070 Transmembrane protein 253 14 21098937-21103724 Predicted membrane proteins Evidence at protein level HPA052329, HPA065092 Supported Mixed Group enriched 7 duodenum: 104.1;small intestine: 102.1 colon: 15.8 TMEM254 bA369J21.6, C10orf57, FLJ13263 ENSG00000133678 Transmembrane protein 254 10 80078646-80092557 Predicted membrane proteins Evidence at protein level HPA029105 Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all skin: 85.9 TMEM255A FAM70A, FLJ20716 ENSG00000125355 Transmembrane protein 255A X 120258650-120311556 Predicted membrane proteins Evidence at transcript level HPA048470 Uncertain Uncertain Nucleus
Nuclear bodies Group enriched Tissue enhanced ovary: 23.4 cervix, uterine: 10.4 TMEM255B FAM70B, MGC20579 ENSG00000184497 Transmembrane protein 255B 13 113759240-113816995 Predicted membrane proteins Evidence at protein level HPA043334 Approved Approved Nucleoplasm Renal cancer:4.12e-5 (unfavourable) Expressed in all Mixed lung: 8.3 TMEM259 ASBABP1, C19orf6, MBRL, MGC4022 ENSG00000182087 Transmembrane protein 259 19 1009648-1021179 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042669, HPA054801 Approved Approved Nuclear speckles
Endoplasmic reticulum Stomach cancer:8.92e-6 (favourable), Endometrial cancer:1.01e-4 (favourable) Expressed in all Expressed in all spleen: 132.3 TMEM262 ENSG00000187066 Transmembrane protein 262 11 65084979-65089375 Predicted membrane proteins Evidence at transcript level Not detected Tissue enriched 57 testis: 13.7 cervix, uterine: 0.2 TMEM266 C15orf27, FLJ38190 ENSG00000169758 Transmembrane protein 266 15 76059837-76229121 Predicted membrane proteins Evidence at protein level HPA041921 Uncertain Supported Plasma membrane
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 1.9;skeletal muscle: 1.5 placenta: 1.1 TMEM33 FLJ10525 ENSG00000109133 Transmembrane protein 33 4 41935120-41960572 Predicted membrane proteins Evidence at protein level Renal cancer:1.35e-5 (favourable) Expressed in all Expressed in all thyroid gland: 39.8 TMEM35 FLJ14084 ENSG00000126950 Transmembrane protein 35 X 101078720-101096364 Predicted membrane proteins Evidence at protein level HPA048583 Supported Tissue enhanced Tissue enhanced cerebral cortex: 42.5;seminal vesicle: 64.8 prostate: 34.0 TMEM39A FLJ10902 ENSG00000176142 Transmembrane protein 39A 3 119429500-119468830 Predicted membrane proteins Evidence at protein level HPA039140 Approved Approved Nucleoplasm
Vesicles Renal cancer:1.00e-5 (unfavourable), Liver cancer:3.26e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 32.9 TMEM41B KIAA0033 ENSG00000166471 Transmembrane protein 41B 11 9280654-9314780 Predicted membrane proteins Evidence at protein level HPA014946 Uncertain Approved Peroxisomes Liver cancer:9.18e-6 (unfavourable) Expressed in all Mixed thyroid gland: 22.3 TMEM47 BCMP1, DKFZp564E153, DKFZP761J17121, TM4SF10 ENSG00000147027 Transmembrane protein 47 X 34627064-34657288 Predicted membrane proteins Evidence at protein level HPA046658 Approved Approved Nuclear membrane Renal cancer:4.05e-6 (favourable), Melanoma:2.10e-4 (unfavourable) Expressed in all Mixed endometrium: 74.9 TMEM54 CAC-1 ENSG00000121900 Transmembrane protein 54 1 32894594-32901438 Predicted membrane proteins Evidence at transcript level HPA061992 Approved Vesicles Liver cancer:3.08e-4 (unfavourable) Expressed in all Mixed colon: 226.8 TMEM57 FLJ10747 ENSG00000204178 Transmembrane protein 57 1 25430858-25500209 Predicted membrane proteins, Transporters Evidence at protein level HPA019680 Approved Cytosol Renal cancer:7.13e-4 (favourable) Expressed in all Expressed in all testis: 36.0 TMEM60 C7orf35, DC32 ENSG00000135211 Transmembrane protein 60 7 77793728-77798580 Predicted membrane proteins Evidence at transcript level HPA062625 Approved Breast cancer:3.09e-4 (favourable), Glioma:8.70e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 55.3 TMEM63B C6orf110, dJ421H19.2, DKFZp434P0531 ENSG00000137216 Transmembrane protein 63B 6 44126914-44155519 Predicted membrane proteins, Transporters Evidence at protein level HPA029249, HPA029250, HPA029251 Uncertain Validated Plasma membrane
Actin filaments Expressed in all Expressed in all lung: 59.2 TMEM72 bA285G1.3, C10orf127, KSP37 ENSG00000187783 Transmembrane protein 72 10 44911200-44937002 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039894, HPA062907 Supported Renal cancer:1.01e-4 (favourable) Tissue enriched Tissue enriched 7 kidney: 54.0 rectum: 8.0 TMEM94 KIAA0195 ENSG00000177728 Transmembrane protein 94 17 75441159-75500090 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008423, HPA050660 Approved Supported Nucleoplasm
Nuclear bodies Pancreatic cancer:2.26e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 54.3 TMEM99 MGC21518 ENSG00000167920 Transmembrane protein 99 17 40819106-40836274 Predicted membrane proteins Evidence at transcript level HPA076359 Approved Cytosol Expressed in all Tissue enhanced testis: 175.7 epididymis: 52.1 TMUB2 MGC3123 ENSG00000168591 Transmembrane and ubiquitin-like domain containing 2 17 44186970-44191731 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043137 Approved Approved Vesicles
Cytosol Expressed in all Expressed in all testis: 48.5 TP53I11 PIG11 ENSG00000175274 Tumor protein p53 inducible protein 11 11 44885903-44951306 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA059727, HPA061276 Uncertain Supported Endoplasmic reticulum
Golgi apparatus Breast cancer:7.33e-5 (unfavourable), Renal cancer:4.65e-4 (unfavourable), Melanoma:6.12e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 58.0 TPCN1 FLJ20612, KIAA1169, TPC1 ENSG00000186815 Two pore segment channel 1 12 113221050-113298585 Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA039757 Approved Expressed in all Expressed in all thyroid gland: 53.3 TPTE2 TPIP ENSG00000132958 Transmembrane phosphoinositide 3-phosphatase and tensin homolog 2 13 19422877-19536762 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA068342 Approved Endoplasmic reticulum
Cytosol Tissue enriched Tissue enriched 33 testis: 11.9 lymph node,tonsil: 0.3 TRPV6 CaT1, ECAC2 ENSG00000165125 Transient receptor potential cation channel, subfamily V, member 6 7 142871203-142885762 Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA062864 Approved Tissue enriched Tissue enhanced prostate: 38.7;salivary gland: 29.3 placenta: 17.4 TSPAN12 NET-2, TM4SF12 ENSG00000106025 Tetraspanin 12 7 120787320-120858402 Disease related genes, Predicted membrane proteins Evidence at protein level HPA051570, HPA058244 Uncertain Approved Vesicles
Microtubules Expressed in all Mixed kidney: 90.9 TSPAN14 DC-TM4F2, MGC11352, TM4SF14 ENSG00000108219 Tetraspanin 14 10 80454166-80533123 Predicted membrane proteins Evidence at protein level HPA014773, HPA057174 Uncertain Supported Vesicles Cervical cancer:3.56e-4 (favourable), Renal cancer:4.20e-4 (favourable) Expressed in all Expressed in all placenta: 128.3 TSPAN16 TM-8, TM4-B, TM4SF16 ENSG00000130167 Tetraspanin 16 19 11296139-11326996 Predicted membrane proteins Evidence at protein level HPA041579 Approved Not detected Tissue enriched 32 testis: 153.1 bone marrow: 4.8 TSPAN17 FBX23, FBXO23, TM4SF17 ENSG00000048140 Tetraspanin 17 5 176647387-176659054 Predicted membrane proteins Evidence at transcript level HPA030447 Approved Nucleoplasm Expressed in all Expressed in all bone marrow: 34.8 TSPAN18 TSPAN ENSG00000157570 Tetraspanin 18 11 44726465-44932421 Predicted membrane proteins Evidence at protein level Expressed in all Mixed smooth muscle: 68.4 TSPAN2 FLJ12082, TSN2, TSPAN-2 ENSG00000134198 Tetraspanin 2 1 115048011-115089500 Predicted membrane proteins Evidence at protein level HPA015640 Uncertain Approved Nucleoplasm Renal cancer:8.48e-7 (unfavourable), Endometrial cancer:8.89e-4 (unfavourable) Mixed Tissue enhanced endometrium: 71.2;smooth muscle: 64.0 seminal vesicle: 40.1 TSPAN3 TM4-A, TM4SF8, TSPAN-3 ENSG00000140391 Tetraspanin 3 15 77041404-77083984 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015996 Uncertain Approved Nucleoplasm
Golgi apparatus Expressed in all Expressed in all epididymis: 519.8 TSPAN31 SAS ENSG00000135452 Tetraspanin 31 12 57738013-57750211 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA057489 Approved Renal cancer:9.91e-5 (favourable), Head and neck cancer:1.09e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 73.1 TSPAN32 PHEMX, TSSC6 ENSG00000064201 Tetraspanin 32 11 2301997-2318200 Predicted membrane proteins Evidence at protein level HPA024135 Uncertain Mixed Tissue enhanced bone marrow: 12.0 heart muscle: 6.8 TSPAN4 NAG-2, TETRASPAN, TM4SF7, TSPAN-4 ENSG00000214063 Tetraspanin 4 11 842808-867116 Predicted membrane proteins Evidence at protein level Liver cancer:1.02e-4 (unfavourable), Glioma:2.57e-4 (unfavourable) Expressed in all Expressed in all spleen: 107.3 TTYH1 ENSG00000167614 Tweety family member 1 19 54415219-54436900 Predicted membrane proteins, Transporters Evidence at protein level HPA023617, HPA050655 Approved Breast cancer:3.64e-4 (favourable) Tissue enriched Tissue enriched 27 cerebral cortex: 57.9 testis: 2.1 TTYH3 KIAA1691 ENSG00000136295 Tweety family member 3 7 2631951-2664802 Predicted membrane proteins Evidence at protein level HPA053520 Uncertain Liver cancer:2.53e-5 (unfavourable), Renal cancer:2.58e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 62.4 TUSC3 MGC13453, MRT7, N33, OST3A ENSG00000104723 Tumor suppressor candidate 3 8 15417215-15766649 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA049851, HPA049974 Approved Thyroid cancer:7.86e-4 (favourable) Expressed in all Mixed epididymis: 140.7 TVP23A FAM18A, YDR084C ENSG00000166676 Trans-golgi network vesicle protein 23 homolog A (S. cerevisiae) 16 10760919-10818794 Predicted membrane proteins Evidence at transcript level HPA060582 Uncertain Approved Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 6.3 ovary: 3.2 TVP23C FAM18B2, MGC8763 ENSG00000175106 Trans-golgi network vesicle protein 23 homolog C (S. cerevisiae) 17 15502264-15563595 Predicted membrane proteins Evidence at protein level HPA019585, HPA065603 Uncertain Validated Golgi apparatus Mixed Mixed thyroid gland: 10.3 TVP23C-CDRT4 FAM18B2-CDRT4 ENSG00000259024 TVP23C-CDRT4 readthrough 17 15436021-15563561 Predicted membrane proteins Evidence at transcript level HPA065603 Approved Golgi apparatus Not detected Mixed parathyroid gland: 11.6 UCP1 SLC25A7, UCP ENSG00000109424 Uncoupling protein 1 (mitochondrial, proton carrier) 4 140559434-140568805 Predicted membrane proteins, Transporters Evidence at protein level Tissue enhanced Tissue enhanced adrenal gland: 3.7 breast: 0.9 UNC50 GMH1, UNCL, URP ENSG00000115446 Unc-50 homolog (C. elegans) 2 98608579-98618515 Predicted membrane proteins Evidence at protein level HPA027009 Approved Liver cancer:4.89e-5 (unfavourable), Breast cancer:4.79e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 105.7 UNC93A dJ366N23.1, dJ366N23.2 ENSG00000112494 Unc-93 homolog A (C. elegans) 6 167271169-167316019 Predicted membrane proteins Evidence at protein level HPA035729 Uncertain Tissue enhanced Tissue enhanced duodenum: 9.9;skin: 17.9 liver: 7.1 UPK1A TSPAN21 ENSG00000105668 Uroplakin 1A 19 35666516-35678483 Predicted membrane proteins Evidence at protein level HPA049879 Supported Tissue enriched Tissue enhanced esophagus: 27.0;urinary bladder: 112.9 skin: 15.6 UPK1B TSPAN20, UPK1 ENSG00000114638 Uroplakin 1B 3 119173517-119205153 Predicted membrane proteins Evidence at protein level HPA031799, HPA031800 Supported Endometrial cancer:3.87e-5 (favourable), Stomach cancer:7.76e-4 (unfavourable) Tissue enhanced Tissue enhanced stomach: 33.2;urinary bladder: 37.5 tonsil: 16.0 VMP1 EPG3, TANGO5, TMEM49 ENSG00000062716 Vacuole membrane protein 1 17 59707192-59842255 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030773, HPA064780 Uncertain Approved Nucleoli
Endoplasmic reticulum Renal cancer:2.77e-8 (unfavourable), Endometrial cancer:1.56e-5 (unfavourable), Liver cancer:8.02e-4 (unfavourable) Expressed in all Expressed in all spleen: 64.7 WLS C1orf139, EVI, FLJ23091, GPR177, mig-14, MRP, wls ENSG00000116729 Wntless Wnt ligand secretion mediator 1 68098473-68233120 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA069520 Approved Supported Endoplasmic reticulum Renal cancer:3.67e-7 (favourable), Urothelial cancer:3.51e-4 (unfavourable), Breast cancer:4.03e-4 (favourable), Ovarian cancer:9.43e-4 (favourable) Expressed in all Expressed in all epididymis: 160.7 WRB CHD5, GET1 ENSG00000182093 Tryptophan rich basic protein 21 39380244-39428528 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018527 Approved Expressed in all Expressed in all fallopian tube: 107.8 XKR6 C8orf21, C8orf5, C8orf7 ENSG00000171044 XK, Kell blood group complex subunit-related family, member 6 8 10896045-11201366 Predicted membrane proteins Evidence at transcript level HPA024828 Uncertain Mixed Mixed testis: 1.8 YIF1A 54TM, FinGER7, YIF1, YIF1P ENSG00000174851 Yip1 interacting factor homolog A (S. cerevisiae) 11 66284580-66289170 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014840 Approved Supported Golgi apparatus
Vesicles
Microtubule organizing center Urothelial cancer:8.70e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 61.2 YIF1B FinGER8 ENSG00000167645 Yip1 interacting factor homolog B (S. cerevisiae) 19 38305104-38317273 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039328, HPA055257, HPA062675 Approved Approved Golgi apparatus
Vesicles Liver cancer:4.53e-5 (unfavourable), Pancreatic cancer:1.88e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 49.6 YIPF1 DJ167A19.1, FinGER1 ENSG00000058799 Yip1 domain family, member 1 1 53851719-53889834 Predicted membrane proteins Evidence at protein level HPA014716 Approved Approved Nucleoplasm Liver cancer:1.34e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 42.1 YIPF2 FinGER2, MGC3262 ENSG00000130733 Yip1 domain family, member 2 19 10922185-10928681 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019902 Approved Approved Golgi apparatus
Mitochondria Expressed in all Expressed in all testis: 73.3 ZDHHC12 FLJ14524, ZNF400 ENSG00000160446 Zinc finger, DHHC-type containing 12 9 128720869-128724127 Enzymes, Predicted membrane proteins Evidence at transcript level HPA059339 Uncertain Approved Nucleoplasm Expressed in all Expressed in all small intestine: 36.5 ZDHHC16 APH2 ENSG00000171307 Zinc finger, DHHC-type containing 16 10 97446131-97457370 Enzymes, Predicted membrane proteins Evidence at protein level HPA039893, HPA040214 Uncertain Supported Nucleus
Nuclear membrane
Cytosol Expressed in all Expressed in all placenta: 31.3 ZDHHC9 CGI-89, CXorf11, ZDHHC10, ZNF379, ZNF380 ENSG00000188706 Zinc finger, DHHC-type containing 9 X 129803288-129843909 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA031814 Uncertain Supported Golgi apparatus
Cytosol Cervical cancer:4.64e-5 (unfavourable), Breast cancer:9.77e-5 (unfavourable), Head and neck cancer:2.45e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 71.2 ZFYVE27 FLJ32919, SPG33 ENSG00000155256 Zinc finger, FYVE domain containing 27 10 97737121-97760907 Disease related genes, Predicted membrane proteins Evidence at protein level HPA037523, HPA069876 Approved Approved Nucleoplasm
Cytosol Colorectal cancer:6.91e-4 (unfavourable), Stomach cancer:7.54e-4 (favourable), Urothelial cancer:7.80e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 33.4 ZMYM6NB ENSG00000243749 ZMYM6 neighbor 1 34981535-34985353 Predicted membrane proteins Evidence at protein level HPA051024 Uncertain Approved Nucleus
Nucleoli Expressed in all Expressed in all placenta: 90.9